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ABSTRACT 
Osteoarthritis (OA) is a debilitating and painful disease that affects upwards of 
one in every eight adults
1,2
. OA influences the entire joint, but is traditionally
characterized by cartilage degradation
3
. OA is a multifactorial disease with genetic,
biological, and biochemical considerations, but there has been a recent shift in scientific 
opinion that the pathological progression of OA stems from an inflammatory milieu 
produced by the feed-forward progressive pathway as evidenced by simultaneous 
cartilage and synovium co-cultures
4–7
. Autologous protein solution (APS) poses as an
intriguing potential OA therapy by possessing a high anti-inflammatory and anabolic 
mediator concentration profile that could potentially mitigate the progression of OA
8
.
A human OA in vitro co-culture model with patient-matched cartilage and 
synovium was validated and used to analyze the effects of APS on OA progression. The 
outcome measures used to assess OA co-culture with and without APS included: cell 
viability, histological, and biochemical assays including enzyme-linked immunosorbent 
assays (ELISA) and dimethyl methylene blue (DMMB) assays. The co-culture model 
exhibited the hallmarks of OA including pathologically progressive cartilage destruction 
and the presence of inflammatory cytokines.  
APS treatment showed encouraging results in mitigating OA as APS treated co-
culture cartilage experienced less chondrocyte cloning and a general increase of anti-
inflammatory mediators within the OA environment. Given these results, APS could be a 
promising OA mitigation therapy to evaluate further in in vivo trials.  
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Osteoarthritis (OA) is the most common joint disease worldwide as well as the 
leading cause of disability among older adults
1,9,10
. OA affects upwards of 1 out of every
8 adults and the number of individuals displaying common risk factors associated with 
OA are on the rise in the U.S. population, which only furthers the need for immediate 
attention to the debilitating effects that make OA such a physical and socioeconomic 
burden
1,10
. Common risk factors associated with OA include: age, trauma, gender,
genetics, obesity, and biomechanical mechanisms
11,12
. These multiple etiologic risk
factors can lead to the induction of inflammatory pathways that are prevalent in 
mediating the progression of OA
13
. A distinct inflamed environment is maintained within
osteoarthritic joints that ultimately leads to the degradation of cartilage and further 
inflammation via degradation products. This cycle of inflammation and degradation 
represents a feed-forward progression that involves multiple tissues within the joint. For 
example, the inflammation found in the synovium produces matrix degrading enzymes 
and pro-inflammatory mediators that damage the cartilage. The damaged cartilage in turn 
not only produces further inflammatory and degradation products, but its degradation 
products also further inflame the synovium causing an increase in the production of 
catabolic mediators
3,14
. The inflammatory process within OA progression is a complex
interplay of signaling pathways that requires a therapeutic agent that can address 
inflammation and its multitude of mediators, including IL-1β and TNF-α.  
2 
Zimmer Biomet has created a blood separation device that generates an 
autologous, anti-inflammatory mediator concentrated blood product, Autologous Protein 
Solution (APS). APS contains an array of anabolic and anti-inflammatory mediators, 
namely Interleukin-1 receptor antagonist (IL-1ra) and soluble tumor necrosis factor 
receptors I and II (sTNF-RI & RII)
8
. Interleukin-1β (IL-1β) and tumor necrosis factor-α
(TNF-α) are the two most prominent pro-inflammatory cytokines associated with OA and 
IL-1ra and sTNF-RI & RII are the natural inhibitors of those pro-inflammatory 
cytokines
15,16,17
. The anti-inflammatory profile of APS makes it a promising potential




Osteoarthritis (OA) is a debilitating, painful disease that affects the entire joint via 
inflammation and degradation pathways, not just the characteristically degraded cartilage. 
The multiple induction pathways that result in the distinctive inflammation mediated 
tissue destruction in OA create a need for a therapy containing multiple anti-
inflammatory mediators as a possible way to mediate OA progression. Autologous 
protein solution ((APS), Zimmer Biomet) is an autologous blood based product that 
consists of anti-inflammatory mediators that may influence the prominent inflammatory 
pathways of OA, thus APS could be a promising OA therapy to analyze. The use of an in 
vitro human explant co-culture model consisting of both OA cartilage and OA synovium 
could be promising method in determining the effects of APS, as the human co-culture 
model would exhibit natural OA progression as well as be able to be donor matched with 
APS. In this study we seek to evaluate the effect of APS in long term, human 
osteoarthritic tissue culture systems in order to investigate the potential therapeutic 
efficacy. Within such exploration, a possible mechanism of action for the APS may be 
generalized. The specific aims of this project include the following:  
AIM 1: To establish an in vitro model of human OA 
Hypothesis: Human cartilage collected from patients undergoing total knee 
replacements and placed long term in a trans-well plate will exhibit degradation 
4 
characteristics typical of natural OA disease progression. Approach: Tissue samples 
underwent viability, biochemical, and histological evaluations to determine if the co-
culture system could simulate the native human disease development. Rationale: By 
establishing a model that exhibits a natural human OA pathological progression, its use in 
future APS studies would determine the effects of APS more accurate to in vivo data.  
AIM 2: To evaluate the cytokine leaching profile of APS 
Hypothesis: The cytokine profile released from APS into the media of an in vitro 
culture system will provide an influx in anti-inflammatory cytokines by the end of the 
culture time period. Approach: The leachate media samples will be biochemically 
assessed via ELISAs to determine the concentrations of prominent pro- and anti-
inflammatory cytokines involved in the pathogenesis of OA. Rationale: Establishing the 
cytokine leaching profile of APS will determine the exposure of pro and anti-
inflammatory mediators due to APS on the co-culture model as well as allow for 
extrapolation of cytokine concentrations generated by the co-culture model as a result 
from APS leachate exposure.  
AIM 3: To assess the efficacy of a single dose of APS in mitigating OA progression in 
vitro  
Hypothesis: A single dose of APS would exhibit OA mitigation effects on the co-
culture model. Approach: Cartilage and synovium samples were assessed for viability, 
biochemical, and histological evaluations to determine the effect of APS on cell viability, 
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glycosaminoglycan (GAG) content, DNA content, prominent cytokine concentrations, 
and characteristic cartilage surface progression of OA. Rationale: The cellular, 
biochemical, and histological assessments would determine if a single dose of APS 
would mitigate the hallmarks of OA within an in vitro human explant co-culture model.  
 
AIM 4:  To evaluate the efficacy of a double dose of APS in mitigating OA progression 
in vitro and compare to the mitigation effects of a single dose of APS. 
 Hypothesis: Due to prolonged exposure, a double dose of APS would exhibit 
improved OA mitigation effects on the co-culture model compared to that of a single 
dose of APS. Approach: Cartilage and synovium samples were assessed for viability, 
biochemical, and histological evaluations to determine the effect of APS on cell viability, 
glycosaminoglycan (GAG) content, DNA content, prominent cytokine concentrations, 
and characteristic cartilage surface progression of OA. This was then compared to the 
single dose study found in AIM 3. Rationale: In comparing the OA mitigation effects of 
a single and double dose of APS of an in vitro co-culture model, a preferential dosing 








CLINICAL SIGNIFICANCE OF OSTEOARTHRITIS 
Osteoarthritis (OA) is a debilitating degenerative joint disease that primarily 
affects those over the age of 65 with almost double the prevalence in women
1,9
.  A 2012 
study suggests that OA affects 250 million people worldwide. It is the leading cause of 
disability among the elderly and it places a huge burden on individuals and society as OA 
is usually accompanied by chronic pain, poorer quality of life, and translates to over $10 
billion (USD) in annual wages lost to OA related absenteeism
1
. OA most commonly 
affects the hands and knees and there currently is no cure or approved disease modifying 
drugs. One of the most common routes of treatment is the palliative, end stage solution of 
a joint arthroplasty with artificial materials. However, it is not usually performed on 
small joints such as those in the hands. Of note, 20% of arthroplasties of the lower 
extremities result in cumbersome and costly revision surgeries
1,18
. Arthroplasty of the 
knee and hip accounts for the bulk of OA related hospitalizations, over the past decade 
the number of annual total joint replacements (TJR) in the US has doubled to over 1 
million procedures, and the younger the patient is when they receive their replacement, 
their chance of needing revision surgery increases
1,18
. To date, there are almost twice as 
many knee replacement surgeries than hip replacement surgeries performed for OA 
indications
19
. The number of TJR procedures are expected to increase to over 3 million 
 7 
annual procedures by 2030 as the elderly population and the indications for the surgery 
broaden amongst the younger adults expand
1
. 
The current objectives for OA treatment plans are to control the symptoms, limit 
progression, and improve the quality of life by increasing joint mobility. However, 
current OA treatments are either ineffective or palliative. Clinically the most important 
issues to be solved include reducing pain and cartilage degradation
9,20
. However, OA 
effects more than just the cartilage within the synovial joint of the knee
2,3,21
. After the OA 
process is initiated through varying multifactorial mechanisms, the effector biochemical 
processes intertwine to damage the cartilage, synovium, underlying bone, meniscus, 
tendon, and ligaments of the knee
3
. The biochemical processes result in not only the tell-
tale breakdown of articular cartilage, but also the formation of osteophytes, subchondral 
bone thickening, and the inflammation of the synovium
11
. Figure 3.1 shows the 
differences between a normal and osteoarthritic knee where the whole joint space 
becomes altered during the course of OA. 
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Figure 3.122: Overall joint effects of OA. The right image depicts the normal joint conditions while the transitional 
arrow represents the general pathological sources of OA. The left image shows the effects of OA on the joint tissues. 
 
ANATOMY AND PHYSIOLOGY OF THE KNEE 
The knee is arguably the most complex synovial joint in the body where the femur 
articulates with the tibia and the patella
23
.  Both of the ends of the long bones and 
posterior portion of the patella are covered in a protective articular cartilage that 
functions to disperse loads of the joint
24,25
. Those cartilage covered areas are enveloped in 
a capsule called the synovium, where the synovium is primarily responsible for 
maintaining and production of the synovial fluid
23,26
. The synovial fluid provides the 
lubrication within the joint and is an ultra-filtrate from plasma that consists of proteins 
including hyaluronic acid and lubricin that are produced by the cells found in the 
surrounding cartilage and synovium as well as the blood plasma proteins such as 
albumin
27,28
. The total joint is considered to be the compilation of the previously 
 9 
described components as well as the supporting tendons, ligaments, and subchondral 




NORMAL CARTILAGE STRUCTURE AND FUNCTION 
Normal articular cartilage (i.e. hyaline cartilage) provides a lubricated articulation 
surface by promoting load dispersal in the joint with a low coefficient of friction
9,29
. It is 
avascular and also lacks innervation and lymphatic vessels. Due to this lack of 
components required for nutrient transport, articular cartilage is inherently limited in its 
ability to heal and regenerate
30
. Diarthrodial or synovial joints are lined with 2-4 mm of 
articular cartilage and it is separated into three separate zones that each consist of their 
own compositions to aid in individual protection for the joint
30,31
. In general, articular 
cartilage is composed of a dense extracellular matrix (ECM) with a chondrocytes 
distributed throughout the ECM, which mainly consists of water, collagen, and 
proteoglycans as well as small amounts of other proteins
30
.   
 
Figure 3.232: Anatomical zones of articular cartilage. The left image illustrates the chondrocyte organization of 
articular cartilage and the right image depicts the collagen fiber orientation within articular cartilage. 
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There are three distinct anatomical zones in articular cartilage, as seen in Figure 
3.2, and each zone functionally contributes a specific resistance to joint loading. The thin 
superficial zone consists of collagen fibrils aligned parallel to the articulation surface as 
well as a greater number of smaller, flatter chondrocytes
30,32
. The collagen alignment aids 
in resisting shear stresses. Maintaining an intact superficial zone is imperative to cartilage 
functionality and therefore it’s imperative to overall joint health
30,33
. The superficial zone 
is responsible for a large portion of the mechanical properties of cartilage and therefore 
serves as the primary defense against physiological wear for the other deeper cartilage 
zones. The superficial zone plays an additional role as a protective barrier and gate to the 
cartilage as the superficial zones comes into direct contact with the synovial fluid
30,32
.  
The middle or transitional cartilage zone is a thicker zone directly underlying the 
superficial zone. It consists of obliquely organized thicker collagen fibrils and 
proteoglycan content in conjunction with a less dense and rounder chondrocyte 
population. This organization serves as a bridge between the superficial and deep zones 
as well as the first protective zone against compressive forces
30,32
.   
The slightly thinner deepest zone is responsible for resisting the larger portion of 
compressive forces as this zone has the thickest collagen fibrils that are organized 
perpendicular to the articulation surface. This zone also contains the least amount of 
water and the greatest fraction of proteoglycan content within articular cartilage, which 
also aid in the protective functionality.  The chondrocyte population in this zone is scarce 




The final characteristic zonal morphology found in articular cartilage is the tide 
mark. This distinguishes the separation between the deep zone and the calcified cartilage 
layer, which is found immediately overlying the subchondral bone. The calcified 
cartilage layer functions to anchor the perpendicularly aligned collagen fibrils from the 
deep zone to the bone, as well as anchoring the cartilage as a whole to the bone
30,32
. 
The different constituents of the matrix vary throughout, but all contribute to the 
overall functionality of articular cartilage. Water is the most prevalent component in the 
articular matrix and accounts for 65% to 85% of the total weight that can mostly be found 
in either intrafibrillar space and in the matrix pore space
30,32
. The relative water content 
fluctuates from a higher content in superficial zones to lower content in the deep zone. 
This difference in water content between the different zones of the cartilage as the water 
is necessary to deliver the inorganic ions and nutrients to the varying populations of 
chondrocytes that inhabit those zones
30
. 
The most abundant type of collagen found in cartilage ECM is collagen type 
II
12,30,32
. Type II collagen represents almost 95% of the collagen found in articular 
cartilage. It is also the most prevalent structural macromolecule in cartilage as the 
individual fibrils form larger fibers that are interlaced with proteoglycans
30,32
. Other types 
of collagen found within articular cartilage are types I, IV, V, VI, IX, and XI, but they 
only minorly contribute in formation and stabilization roles of the larger type II fibril 
network
30
. Structurally, collagen is a triple helix of polypeptide chains where the chains 
are composed of glycine, proline, and hydroxyproline amino acid pattern. The structure 
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of type II collagen imparts the collagen, and therefore cartilage, with shear resistive 
properties as well as tensile resistive properties
30
. 
Proteoglycans are the second most prevalent macromolecule found in the cartilage 
ECM
30,32
. They are comprised of a single core protein with at least one additional 
glycosaminoglycan (GAG) chain attached. The chains linearly extend from the core 
protein and maintain a certain degree of separation between the chains as they are 
composed of 100 or more monosaccharides and are distinctively negatively charged
30
. 
This negative charge contributes to the cartilage’s ability to retain water within the 
ECM
30,33
. The most ubiquitous proteoglycan is aggrecan, which consists of many 
chondroitin sulfate and keratin sulfate chains. Aggrecan is especially distinguished from 
the other proteoglycans for its ability to form large proteoglycan aggregate chains with 
hyaluronan operating as a backbone via link proteins. Aggrecan also contributes to 
cartilage’s vital role in compressive load resistance as it provides the characteristic 
osmotic properties of the tissue due to the water retention resulting from the presence of 
the negatively charged GAG
30,32
. Although the other proteoglycans present in cartilage 
are nonaggreagating, they still play important roles like providing structural support 
within collagen interactions. Most notably, decorin and fibromodulin function in 
fibrillogenesis and interfibril communications and bigylcan interacts with collagen VI
30
. 
Figure 3.3 shows the structure of these macromolecules and there general interactions 
within their ECM environment. 
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Figure 3.330: Structural interactions of cartilage ECM macromolecules. The image highlights the interconnectivity 
of the two prominent macromolecules, collagens and proteoglycans, as well as the interactions of the lesser present 
smaller molecules.  
Chondrocytes are the specialized cells that inhabit the cartilage. They function in 
the development, maintenance, and repair of the ECM. They only consist of 2% of the 
total volume of articular cartilage. Chondrocytes also vary in size, shape, and number 
between the formative layers of cartilage. They respond to a multitude of stimuli like 
growth factors, mechanical and piezoelectric influences, and hydrostatic pressures, 
although they rarely have any direct cell-to-cell communication as chondrocytes are 
characteristically trapped within their microenvironments in structures called lacunae
30
. 
Due to many factors including cartilage’s anatomical composition and the chondrocyte 
microenvironment, chondrocytes are limited in their ability to replicate. This directly 




NORMAL SYNOVIUM STRUCTURE AND FUNCTION 
Synovium refers to the soft tissue that lines the diarthroidal joints, which is 
comprised of an inner or deep layer of intima and an underlying superficial layer of 
subintima tissue depicted in Figure 3.4
34,35
. The intima is the continuous layer of cells 
that directly lines the joint and includes characteristic cell populations such as 
macrophages and fibroblasts. Alternatively, the subintima consists of blood and 
lymphatic vessels and fibroblasts dispersed among a collagenous ECM
34,35
. In between 
these layers is a small layer of fluid abundant in hyaluronan; this allows the tissue to be 
non-adherent. An intact non-adherent surface is an essential function of synovium as it 
allows a continuous movement of the membrane without frictional interference
35
. 
Preserving this frictionless movement contributes to one of the primary functions of 
synovium where it is able to deform in order to accommodate the other non-deformable 
tissues present in the highly mobile joint environment
28,35
. Other important functions of 
synovium include controlling the composition and volume of synovial fluid, cartilage 





Figure 3.434: Synovial intimal and subintimal layer composition. The image illustrates the cellular components and 
vasculature location within the layers of the synovium.  
An undamaged synovial surface is vital as it retains the synovial fluid in the joint 
space
34,35
. It allows the transportation of crystalloids and other proteins while 
simultaneously inhibiting the rapid exchange of hyaluronan. Maintaining a specific ratio 
of hyaluronan in the synovial fluid is important for joint loading recovery
35,36
. The 
permeable matrix structure of synovium allows for the easy transport of nutrients from 
the vascularized synovium to the joint space where the nutrients can be utilized by 
avascular tissues such as the cartilage
35
. The matrix consists of type I, III, and V 
collagens, as well as hyaluronan, chondroitin sulfate, biglycan, decorin proteins, and 
fibronectin all form the matrix architecture in a heavily cellularized environment
28
. The 
vascularized nature of the synovium is important as it provides nutrition to the synovial 
cells, but also provides additional cell recruitment to the tissue
35,37
. Other monocytes and 
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perivascular fibroblasts are recruited to the area and then matured into tissue 
macrophages and intimal fibroblast precursors respectively.  
The lubrication of the cartilage surface is due to glycoproteins, especially lubricin 
and superficial zone protein. Synoviocytes also secrete proteoglycan 4 (PRG4) and are 
the major source for surface active phospholipids, which are additional molecules that aid 
in lubrication. The chondrocytes in the superficial layer of articular cartilage also secrete 
PRG4
28
. Hyaluronan could play a possible role in maintaining an important lubricant film 
on the cartilage surface; however, its chief role within the joint is preserving the constant 
level of fluid during motion
28,35
. The constant level of fluid provides a cushion during 
exercise and ultimately is another protective entity for the cartilage and synovium tissue. 
The constant volume is maintained by mechanical stimulations where the body senses the 
change in fluid volume via mechanical cues and stimulates a change in the rate of 
hyaluronan synthesis
35,36
. The rate of hyaluronan synthesis works directly to influence the 
synovial cushion as a high synovial fluid volume causes an increase of the mechanical 
stresses on fibroblasts (high pressure on synovial wall) and therefore results in a 
reduction in the hyaluronan synthesis rate and vice versa for low synovial fluid volume
35
.  
The extensive network of lymph vessels in the subintimal synovium also aid in 
synovial fluid volume as they are responsible for the clearance of proteins and  
macromolecules present in the synovial fluid
28
. The normal turnover time of synovial 
fluid constituents is approximately 1 hour, but the turnover time for larger molecules such 
as hyaluronan is approximately 13 hours. Any diffusion or synovial fluid turnover 
association with hyaluronan can result in slower turnover time independent of molecule 
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NORMAL SYNOVIAL FLUID COMPOSITION AND FUNCTION 
Synovial fluid or synovia is dialysate of plasma which contains similar levels of 
glucose and uric acid to plasma, but lower levels of protein
28
. This is due to the filtration 
system that is imposed upon synovial fluid from the double –barrier membrane that the 
surrounding synovium creates
28,35
. This ultrafiltrate is then combined with the hyaluronan 
previously synthesized by the synovium to constitute the synovial fluid
27
. A normal knee 
joint contains approximately 4 mLs of colorless synovial fluid, when an inflammatory 
pathology is induced to the joint the color becomes cloudy and slightly yellow
27
. 
Synovial fluid is highly viscous due to the large concentration of polymerized hyaluronan 
present. This only aids in its function to resist compressive forces
27,39
.  
Synovial fluid contains the same proteins found in plasma, but in smaller, almost 
negligible amounts. The normal range for protein levels in synovial fluid is 1-3 g/dL, 
however arthritis and other arthropathies commonly display increased protein content
27,40
. 
Normal synovial fluid also contains small amounts of white blood cells. The distribution 
of the nucleated cells is: 48% monocytes, 24% lymphocytes, 10% macrophages, 7% 
neutrophils, and 4% synovial fibroblasts
27
. The presence of crystals within the synovial 
fluid can be indicative of disease or trauma, where cholesterol crystals imply either 
osteoarthritis or rheumatoid arthritis and corticosteroid crystals appear in the synovial 
fluid after intra-articular injections
27
.  A complex environment of regulatory cytokines is 
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present within the synovial fluid as well. Inflammatory pathologies increase the 
concentration of inflammatory cytokines that can down-regulate the synoviocyte 





NORMAL AUXILLARY JOINT SUPPORTING STRUCTURE AND FUNCTION 
The additional supporting joint structures like bone, ligament, and tendon also 
take part in joint pathologies as they all share a common joint space and are exposed to 
similar pathologic milieus. The bone directly underlying the calcified cartilage is referred 
to as the subchondral bone. It is composed of two different anatomical regions: the 
subchondral end plate and the subchondral trabecular bone. The cortical end plate is a 
non-traditional architecture where its distinct porosity allows for a resultant 
communication between the cartilage and bone. This communication includes a high 
number of blood vessels and nerves leading from the bone into the calcified cartilage 
layer
41
.  These pores are greater in number in areas of high loading; this could be due to 
the thicker areas of cartilage that are required to support those heavily loaded areas, thus 
more nutrients and signaling can reach the greater areas of cartilage
41,42
.   
Ligaments stabilize the joint with their collagen–rich fiber structure. Tendon 
consists of a large portion of collagen I that forms by collagen fibers aligning in a highly 
organized hierarchal arrangement
43
. Although tendon and ligament tissue is similar in its 
biochemical components, ligaments have a much greater percentage of elastin whereas 
tendon has a slightly higher percent composition of collagen as well as a more organized 
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fiber structure when compared to ligament tissue
44
. In order to transfer motion and to 
stabilize the joint, the matrix of tendon and ligaments respectively need to be able to 
resist considerable loads. However, inflammatory pathologies cause a breakdown of this 
highly aligned collagen structure to the point where their ability to resist loading could be 
affected
45
. Although we see that tendon and ligaments are affected in inflammatory 
situations, tendon or ligament injuries have been linked to induce osteoarthritis as the 
supporting tissue injuries lead to a general loosening of the joint and irregular loading 




BIOMECHANICAL CONCEPTS OF NORMAL JOINT MOTION 
Cartilage is able to resist compressive loads and maintain integrity during 
mechanical responses due to the consistency of the ECM
24
. The aggregan molecules 
swell with water due to the negatively charged proteoglycans, but the swelling is 
restricted by the collagen framework. This forces the aggregates into a closer proximity 
and when compressive loads are applied, the negatively charged aggregan increases the 
mutual repulsive force. This increase in repulsive force reinforces the compressive 
stiffness of the cartilage
33
. Degradation to the collagen matrix loosens the collagen 
framework and therefore aggregan is not trapped as efficiently and reduces the 
compressive stiffness of cartilage
33,46
. Accurate mathematical modeling of the mechanical 
response of cartilage is possible due to the recognition of the interdependence of fluid 
flow and deformation. As a result of this recognition, cartilage is referred to as a mixture 




The biphasic model separates the solid components of cartilage such as the 
proteoglycans, collagen, and cells and models those as an incompressible elastic material, 
while the interstitial fluid of the cartilage is modeled as incompressible and as having no 
viscosity. Therefore under compressive loads, cartilage is modeled as an incompressible , 
elastic solid where the flow of fluid through the cartilage is so slow there is not enough 
time for fluid expansion under rapid, physiological loads
33,47
. This homogeneous 
isotropic biphasic model explains confined compression creep and stress-relaxation 
experiments sufficiently, however, it is important to note that this general theory does not 
adequately simulate all transient aspects of cartilage behavior and depending on the 
desired parameter, more specific models need to be applied
47
.  
Lower extremity joints can experience forces up to ten times the body weight. 
Due to this, analysis of tribological principles of the knee is important for diagnostic and 
therapeutic reasons
36
. Biochemical and mechanical factors can contribute to alterations of 
joint lubrication and friction
36,48
. The normal lubrication classification of the knee is 
dependent on the interval of dynamic loading that the joint experiences and because of 
this, there exists a leading theory of multimodal lubrication
36,48,49
. The general theory is 
that the knee experiences fluid-film lubrication during high velocities where the femur-
tibia contact is avoided due to the viscous forces of the synovial fluid and its ability to 
fully support the load. During low or zero velocity, a mixed regime is present where 
boundary lubrication is the dominating profile
36
. Boundary lubrication functions as a 
regime by carrying the load on the surface asperities, or raised solid features of the 
cartilage surface as oppose to the synovial fluid lubricant. Due to this lubrication regime, 
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it is important to understand the coefficient of friction associated with the diarthroidal 
joint in synovial fluid, 0.002 to 0.02, and that it does not necessarily increase due to 
osteoarthritis
36,50
. Theories surrounding the decrease of interstitial fluid pressure in 





THE EFFECT OF OA ON ALL JOINT TISSUES 
A singular preeminent cause of OA has yet to be determined; however, it has been 
linked to many different risk factors including age, gender, a previous joint injury, 
genetic predisposition and mechanical contributions including malalignment
1,11,13
. 
Although OA is a complex, multifactorial disease, the affected OA patients possess 
common pathological pathways that influence the entire joint
11,12
. A prospective view of 
the disease is to treat the joint as a whole organ due to this total joint influence
3
. These 
biochemical and histological changes ultimately lead to pain and loss of function. The 
entire joint is affected from cartilage degradation to synovial inflammation as well as 
osteophyte formation and general degradation of the tendon, ligaments, and meniscus
3,12
.  
The superficial zone of articular cartilage experiences high shear mechanical 
forces and is the earliest affected area during OA as pathological progression begins at 
the points where mechanical shear forces are highest
30,31
. Normally, chondrocytes are in a 
quiescent state where they have low matrix turnover and proliferation. During OA, the 
chondrocytes become senescent and form proliferative cell clusters
31
. This increase in 




. This clustering could be considered as an injury response where the cartilage 
attempts to correct damage, when given mechanical stimuli, by creating more 
chondrocytes to aid in remodeling. However the chondrocyte usually mature to an 
abnormal hypertrophic chondrocyte population
3,51
. It is thought that these chondrocyte 
clusters produce stress concentration points within the tissue, which are particularly 
detrimental to areas with high compression and shear forces. Those stress concentration 
points can usually be found in close proximity to fissures within the cartilage and 
ultimately those fissures result in that portion of the cartilage to break off into debris 
within the synovial fluid
51
.  
This cartilage debris within the joint space colludes with the inflammatory 
mediators present in the synovial fluid to further the pathogenesis of OA by increasing 
the frictional components and therefore decreasing the lubrication in the overall joint
12
. 
The matrix degrading enzymes produced are aggrecanases and collagenases, which break 
down the two main components of articular cartilage
10,29
. These matrix degrading 
enzymes belong to the matrix metalloproteinase (MMP) family and there are several 
other serine and cysteine proteinases included in that group as well
3
. Cartilage 
degradation differs in primary malefactors from early to late stage OA. Early stage OA 
could be more responsive to MMP-3 and A Disintegrin and Metalloproteinase with 
Thrombospondin Motifs 5 (ADAMTS-5) while later stage OA has numerous 
inflammatory mediators and biomarkers that are typically present in lower concentrations 




The increase in MMP-3 and ADAMTS-5 leads to an increased degradation of 
aggrecan followed by an upregulation in the collagen II degrading collagenase, MMP-13. 
Once the cartilage has been severely compromised by degradation, cartilage reaches a 
detrimental point of no return in terms of cartilage remodeling due to the extremely low 
turnover rate of collagen II
3,10,29
. The increased concentration of aggrecanases and 
collagenases work to degrade the ECM; and usually the aggrecans are the first matrix 
element to be affected by OA and are generally depleted corresponding to the severity of 
the disease progression. These aggrecans are cleaved from the aggregate chains by the 
aggrecanases, where the degraded fragments can rapidly diffuse from the cartilage
5,11,16
. 
Normal proteoglycan content remains in the matrix and this can be used to combat the 
disease progression, but OA progression leads towards the loss of the hyaluronic acid 
backbone of the remaining aggregate. The compromising of the backbone critically 
affects the remaining cartilage’s ability to maintain its proteoglycan content
24
.  
In early OA, the concentration of MMP-13 is greater in the middle and deep 
cartilage zones due to the number of chondrocytes that produce MMP-13 as well as the 
high collagen content found in those zones and a greater concentration of aggrecanases in 
the superficial layer
11
. The chief aggrecanases in OA are ADAMTS-4 (aggrecanase-
1)and ADAMTS-5 (aggrecanase-2) and they can be induced either inherently within the 
cartilage or upon stimulation from cytokine signaling
26
. These aggrecanases breakdown 
the structural chains of cartilage and weaken the cartilage’s ability to resist shear forces 
and when this is combined with the collagenases degrading the compression resistant 
collagen content majorly found in the deeper layers, the overall structure of cartilage is 
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impaired and susceptible to damage from physiological forces
11,24
. This process forms a 
positive feedback loop as the catabolic activity only furthers degradation and increases 
the production of additional catabolic mediators like cytokines and aggrecanases
5,26
. 
Figure 3.5 shows a snapshot of this molecular pathogenesis of OA. 
 
Figure 3.511: Molecular profile of OA progression. The image illustrates a glimpse of the complex feed forward 
progression of OA as the cartilage and the synovium increase each other’s pathogenesis by generating matrix degrading 
enzymes and inflammatory cytokines. 
Synovitis has been increasingly linked to not only contributing to disease 
progression, but it has also been implicated as a primary factor in the development of 
OA
11,26
. Synovitis is detected via MRI in early and late stage OA, even when the joint 
could not be clinically diagnosed from traditional radiographical imaging and it is 
characterized by hyperplasia and an increased mixed macrophage infiltration not only 
within the synovial lining, but also throughout the tissue
26
. The inflammation of the 
synovium correlates with the biological markers that are a hallmark of inflammatory 
disorders
13,26




synovium not only produces inflammatory chemokines and cytokines, but matrix 
degrading enzymes as well
11
. OA synovium most notably produces interleukin-1β (IL-
1β) and tumor necrosis factor α (TNF-α), which are proposedly the principal 
inflammatory cytokines driving OA progression
5,11,53
. Synovium also inherently produces 
cartilage matrix degrading enzymes such as MMP-1 and MMP-3. The overproduction of 
the inflammatory mediators including cytokines and growth factors from the hyperplastic 
synovium could have a significant effect on the pathophysiology of OA, especially since 
early stage OA is cytokine driven
26
.   
The cartilage and the synovium contribute to each other’s degradation in a feed-
forward progression. The cytokines produced by each of the tissue correspond to 
receptors or affect via pathological progression in the opposing tissue
10
. The matrix 
degrading enzymes produced by the synovium degrade the cartilage matrix and 
ultimately result in the release of the degraded matrix fragments. Those fragments then 
collaboratively progress OA by binding to synovial cell receptors to propagate 
inflammation as well as increasing the friction that the joint would experience in 
pathophysiological movements by disrupting the lubrication boundary layer
11,34
. This 
disruption in the lubrication boundary layer then signals for an increase in the generation 
of inflammatory mediators from cartilage and synovium
24
.  This is a general overview of 
one of the multiple roles of pathological progressions the two tissues play.  
The inflammatory environment affects the other tissues in the joint as well, 
especially since the synovial fluid constituent clearance rate for OA knees is negatively 
affected
40,54
. The lymphatic system responsible for the turnover of synovial fluid has been 
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shown to decrease in lymphatic vasculature and therefore prolong inflammatory 
environment exposure in the joint space
54
. This extended exposure could be connected to 
the affects experienced by the other tissues in the joint.  
The subchondral bone experiences major changes in vascularity and bone 
turnover or remodeling. Subchondral sclerosis can occur especially in late stage OA 
where the subchondral bone increases in density or becomes thickened and is attributed 
to severe joint pain
41
. Osteophytes are another alteration in the underlying bone structure, 
where a potential osteophyte formation theory entails that the decrease in mechanical 
loading strength of the cartilage resulting in a higher load being supported by the 
subchondral bone
41,55
. The abnormal loading leads to additional ossification of cartilage 
outgrowths in order to accommodate such loads
55
.  Figure 3.6 shows these pathogenic 
alterations to the subchondral bone.  
Due to the bone’s inherent ability to repair and adapt to its environment, as well 
as its ability to produce signaling molecules such as cytokines, this creates a high 
potential for the subchondral bone to be an important effector in the pathogenesis of 
OA
5,41
. However, more research needs to be conducted to prove the chronological 
production of OA stimulatory cues of subchondral bone
5
. Instability within the joint 
stabilizing bands of dense regular connective tissue especially the ligaments are also 
features in the pathology of OA as the inflammatory environment contributes to their 
degradation
36,42
. The joint is affected as a whole and should be thought of for future OA 
therapeutics as a multi-tissue effector.  
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Figure 641: Osteoarthritic progression on subchondral bone. The image illustrates the progression of OA and its 
specific subchondral effects. 
 
INFLAMMATION ASSOCIATED PRINCIPLES OF OA 
The inflammatory pathways responsible for the pathogenesis of OA are linked to 
a cytokine driven route of progression. The main inflammatory cytokines proposed for 
the progression of OA are IL-1β and TNF-α
5,10,11,29
.  These pro-inflammatory cytokines 
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work collectively since the macrophage population prompts the leading production of 
both cytokines and neutralizing IL-1β and TNF-α creates a similar effective results as 
macrophage depletion in OA cultures
26
. However, there are other inflammatory 
mediators, such as IL-6 and IL-8, and inhibiting one cytokine is not adequate to offset the 
total inflammatory response
10,29
. Although the pathways for inflammation have redundant 
routes, it seems that altering one pathway, such as the IL-1β, does not create an 
upregulation of the other pathways. When both IL-1β and TNF-α are inhibited, there is a 





PRO INFLAMMATORY MEDIATORS IN OA 
IL-1β is a member of the IL-1 family and is responsible for prominent roles in 
cartilage matrix breakdown as well as stimulation of the debilitating nociceptive 
pathways
10
.  IL-1β represses ECM component synthesis by inhibiting collagen II 
expression and promotes cartilage degradation by stimulating MMPs  (1,3, and 13) and 
ADAMTS-4 & 5 in synovial fibroblasts and chondrocytes
10,12
. It also induces other illicit 
responses from other inflammatory cytokines to generate an additive inflammatory 
response
10
. It directly affects the cellularity of the cartilage as IL-1β has been linked to 
causing apoptosis in chondrocytes via nitric oxide (NO) and the viability of chondrocytes 
is an imperative measure to maintaining cartilage homeostasis
12
.   
Another member of the IL-1 family that is present during OA is IL-1α. IL-1α is 
suggested to be an early stage OA marker for humans, where it is present in high 
 29 
concentrations compared to that of its late stage OA indicator counterpart, IL-1β
52
.  Due 
to a majority of human tissue samples being taken from late stage OA patients, this 
literature review will focus on IL-1β synthesis and downstream pathological effects. 
Typically IL-β is found in vivo in modest concentrations as synovial fluid samples 
suggest a concentration of <5.0 pg/ml in late stage OA patients, however studies have 
shown that OA chondrocytes display an increased sensitivity to IL-1β up to four times 
that compared to normal chondrocytes
7,56
.  
The primary source of IL-1β is monocytes and macrophages, but IL-1β does not 
have a traditional secretory pathway where IL-1β can also be released from previously 
activated cells via capase-1 cleavage of the amino-terminal region in order to potentially 
increase its pathological potency
16
.  Perhaps a reason this cytokine is able to be recycled 
is that it has the lowest binding affinity for the IL-1 receptors out of the IL-1 family. IL-
1β can bind to IL-1 receptors I and II (IL-1RI, IL-1RII). However, only IL-1RI contains 
cytoplasmic domains associated with toll-like receptors (TLRs), which the activation of 
TLRs is one of the main activation pathways in the inflammatory hierarchy. Therefore 
IL-1RII is thought of as a decoy receptor as compared to IL-1RI. IL-1RII can be found 
membrane bound or soluble to act as an inactive binding site for active IL-1 cytokines 
and therefore a natural inhibitor
16
.  
TNF-α is another inflammatory cytokine thought to be another primary driver of 
OA
17,25
. It works synergistically with IL-1β in order to produce similar degradation 




. TNF-α stimulates MMP-1,3, and 13 as well to stimulate cartilage matrix 
resorption and promote the downregulation of proteoglycan synthesis
12
.  
TNF-α is produced by multiple cell types, but most notably it has been linked to 
epithelial cells, leukocytes, and macrophage production
57
. TNF-α stimulates the 
production of other cytokines in a cascade of inflammatory responses, such as IL-1, IL-6, 
and IL-8, but it has an especial debilitating effects where TNF-α binding to both of its 
receptors can directly induce neuropathic pain
10
. TNF-α binds to its receptors I and II 
(TNF-RI and RII) with a high affinity and the receptors can be found on almost all cell 
types as well as a soluble and therefore natural inhibiting form
58
. As with IL-1β, TNF-α is 




Other notable inflammatory mediators within the realm of OA are: IL-6, IL-8, and 
NO. Interleukin 6 (IL-6) is a pro-inflammatory cytokine that aids in the shift of cartilage 
homeostasis to that of a catabolic nature by upregulating the production of MMP-1 and 
13. IL-6 functions in combination with IL-1 along with other inflammatory 
mediators
12,29
. IL-8 is another pro-inflammatory cytokine stimulated in the surge of 
inflammatory cytokines induced by TNF-α and is involved in the cartilage degradation 
pathway
10
. NO is a pro inflammatory mediator linked to causing apoptosis of 







ANTI-INFLAMMATORY MEDIATORS OF OA 
The primary naturally occurring inhibitor of IL-1β is interleukin-1 receptor 
antagonist (IL-1ra)
15,16,56,60
. IL-1ra has multiple isoforms, of those; two isoforms inhibit 
the traditional IL-1 inflammatory effects
16,60
. Those isoforms arise from 
keratinocytes/epithelial cells, monocytes, neutrophils, macrophages, fibroblasts, and 
endothelial cells
16
. IL-1ra binds to the active IL-1RI with more affinity than IL-1β, which 
aids the body in inhibiting inflammatory responses via IL-1 activation. IL-1ra is 
systemically present in normal serum at 300 ng/ml concentrations and maintaining a 
particular anti-inflammatory balance between the IL-1β/IL-1ra ratio has been contributed 
to preventing organ damage in IL-1 mediated diseases
16
. Specifically within the 
osteoarthritic joint, a ratio heavily favoring IL-1ra over IL-1β has shown acute improved 
responses to diagnosed patients
16,15
.  
Other naturally occurring anti-inflammatory cytokines are soluble receptors for 
TNF-α (sTNF-RI and sTNF-RII)
57,58,61
. These soluble receptors are produced by shedding 
from the multiple myelocyte cells that produce them, most notably are neutrophils and 
macrophages. TNF-α binds to these receptors after they are no longer membrane bound 
and act as anti-inflammatory cytokines by inhibiting the action of TNF-α
61
. An imbalance 
between the sTNF-Rs and TNF-α has been shown to aid in the diagnoses of inflammatory 
diseases other than osteoarthritis. When the imbalance favors TNF-α, the low 
concentrations of sTNF-Rs actually function as a stabilizer in the binding of TNF-α to the 
membrane bound receptors.  High concentrations of sTNF-Rs attenuate the pathological 




The inflammatory pathway in OA is a complex multiple-route system that 
ultimately degrades the cartilage and negatively affects the other tissues found in the joint 
environment. IL-1β and TNF-α work synergistically as the proposed forerunners in this 
cascade of inflammation by activating the NF-κB transcription factor and MAPK 
pathway to elicit a cellular response from the binding of the inflammatory cytokines
5,11,17
. 
This cellular response includes the upregulation of MMPs and ADAMTSs, which have 
been previously described to execute the matrix destruction
5,10
. Alternatively IL-1β and 
TNF-α also induce the production of IL-6, IL-8, and RANTES, which leads to a further 
increase IL-6 production
10
. The generation of IL-6 ultimately ends with increased 
generation of MMPs and ADAMTSs. Additionally, IL-1β and TNF-α work through 
auxiliary pathways to increase prostaglandin E2 (PGE2) generation via cox-2 in order to 




CURRENT TREATMENTS TARGETING OA  
Surgery is a palliative, end-stage solution to OA that could lead to revision 
surgeries. The first step upon an osteoarthritic diagnosis is to incorporate non-surgical 
therapies into the patients’ overall treatment in order to prolong the natural joint, to help 
relieve the associative pain, and to improve movement within the affected joint. The first 
phase of non-surgical treatments includes non-invasive life style changes like increased 
water and strength training exercises as well as educating the patients on their condition, 
the available therapies, and what they can expect of their condition in the future
62
. The 
next phase in OA management is the introduction of non-steroidal anti-inflammatory 
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drugs (NSAIDs) either in topical formulas or oral medication forms and then patients can 
excel to more invasive options like intra-articular injections
62,63
. The current leading 
therapies used to treat OA with intra articular injections are viscosupplementation, stem 
cell therapies, and the use of biologics.  
Viscosupplementation refers to the supplementation of the viscoelasticity of the 
synovial fluid where intra-articular injections of hyaluronan or hyaluronic acid (HA) aid 
the osteoarthritic joint in protecting the cartilage from further degradation. HA synthesis 
in OA joints is disrupted by the inflammatory cytokine environment, which leads to a 
disruption in the lubricating and viscoelastic properties of the joint or rather its ability to 
cushion the physiological loads
64,63
. Through the catabolic shift in joint environment, the 
natural, high molecular weight HA becomes degraded into low molecular weight HA
11,63
. 
Not only can low molecular weight HA be pro-inflammatory, but it no longer facilitates 
the nutritional maintenance duties of the joint
14,63
.  
The idea behind these HA intra-articular injections is that the injected high 
molecular weight HA will supplement the cleaved OA-affected HA within the joint in 
order to maintain the integrity of the joint. HA can potentially modify OA itself by 
stimulating chondrocyte growth to promote intrinsic healing and repair of the cartilage
63
. 
HA also has the potential to decrease apoptosis and stimulate cartilage matrix 
constituents production such as collagen, proteoglycan, and other hyaluronans
20,63
. There 
are currently 8 different FDA approved HA intra-articular injections available for clinical 
use. Those include: Synvisc®, Synvisc One®, Monovisc®, Hyalgan®, Supartz®, 
Orthovisc®, Gel-One®, and Euflexxa®. They are mostly naturally derived before 
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purification and range in a molecular weight of 500-6000 kDa. They also require their 
patients to come for an average of 3 injections, with the exception of Sinvisc One® 
requiring a single injection. However, one of the major issues with this therapy is that it 
only provides patients with temporary pain relief and therefore temporary increased 
motility. On average the improvement did not last more than 14 weeks after the 
recommended treatment dosages
63
. Studies have suggested that HA intra-articular 
injections to provide a longer term benefit when compared to corticosteroid intra-articular 
injections
62,63
. Even though the exact mechanism of action for these HA intra-articular 
injections have yet to be solidified, they do provide a temporary relief in pain as well as 
temporary increased functionality of the joint
63
.  
Stem cells pose an interesting potential therapy for OA. There are two primary 
types of stem cells used in clinical scenarios. Bone marrow derived stem cells (BMSCs) 
and adipose derived stem cells (ADSCs). Each of these populations of mesenchymal stem 
cells (MSCs) offer advantages and disadvantages to the mitigation of OA. The 
advantages to MSCs are that they are inherently anti-inflammatory, immunomodulatory, 
and can theoretically be autologously applied, meaning the OA patient could potentially 
isolate stem cells from these respective locations in their body and inject their own cells 
intra-articularly
65,66
. There have been previously published works on the effectiveness of 
the clinically used stem cell populations with OA treatment indications, and they have 
possessed moderate regenerative and OA mitigation success
67,68,69
. Encouraging data has 
been presented that MSCs have potential to prevent post-traumatic OA, to regenerate 
fibrillated cartilage surfaces, and reduce pain in patients
66
. However, both clinically used 
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populations would provide the patient with a selectively small yield and it has been 
shown that stem cells work best for OA mitigation when they are injected at high 
concentrations
65
. Stem cells pose an interesting OA therapy with their 
immunomodulatory and inherent anti-inflammatory properties, but their drug 
classification makes going through the regulatory process extremely difficult in the U.S., 




The FDA regulatory pathways for drugs and biological devices are two separate 
hurdles for medical products to overcome in order to be marketed products compared to 
device pathways. The drug approval pathway is a pervasive process where the drug must 
be first developed, characterized, and then tested in animals. After animal testing 
completion, the drug company must submit an Investigational New Drug (IND) 
application which include the composition and manufacturing strategies for the drug as 
well as a fully developed plan for human clinical trials. After the discovery and screening 
phase, the drugs must go through a three phase clinical trial process where the number of 
patients in the trial significantly increases. The FDA focuses during this clinical trial 
phase on safety and effectiveness specifically. After a successful clinical trial, the drug 
company applies for a New Drug Application (NDA). During this time, the labeling and 
the manufacturing facilities of the drug are reviewed along with the NDA application. 
Upon approval, the drug can then be assessed in a post-approval risk capacity where the 
FDA facilitates an easier way for clinicians and consumers to report adverse effects in 




The general pathway for biological devices to be approved by the FDA is just as 
complicated as the drug pathway where biologic must undergo the same general steps as 
a drug except a biologic can submit an IND or an Investigational Device Exemption 
(IDE) at the appropriate time considering what their specific product entails. Another 




Both drug and biologic approval pathways are long and arduous. The pure device 
regulatory pathway is significantly easier in that it can be separated into two routes: pre-
market approval (PMA) and 510(k) approval. The 510(k) route is a less extensive path 
where the product in question is extensively characterized to illustrate substantial 
equivalence to a predicate device already 510(k) cleared. The new device can be 
approved if it is proven to have minimal differences compared to the predicate device. 
The PMA route entails additional clinical trials to the extensive characterization of the 
device and is required for class III devices
72
. The drug and biologic approval processes in 
comparison to the device process is a much more extensive and thorough process that 
could limit companies in their ability to achieve market status for their therapies.  
The FDA defines a biologic as: a virus, therapeutic serum, toxin, antitoxin, 
vaccine, blood, blood component or derivative, allergenic product, protein (except any 
chemically synthesized polypeptide), or analogous product, or arsphenamine or 
derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable 
to the prevention, treatment, or cure of a disease or condition of human beings
73
. A recent 
analysis of clinical trials encompassing OA treatment via biologics indicate that there are 
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two different approaches: one being inhibiting the inflammatory cytokines and two being 
introducing more regenerative growth factors into the environment to stimulate self-
regeneration within the cartilage
74
.  
Inhibition of the inflammatory cytokines involves injections either systemically or 
intra-articularly given the location of the effected OA joint. IL-1β, TNF-α, and β-nerve 
growth factor (β-NGF) have been recently explored as viable cytokine inhibition targets 
in biological OA treatments. IL-1ra (Anakinra) was administered intra-articularly into the 
knees of OA patients and improved pain scores were experienced at first. Inhibition of 
IL-1RI via induction of a monoclonal antibody against IL-1RI, AMG 108, and showed 
little pain score improvements and there were adverse effects associated with that clinical 
trial
74
. To date, IL-1β inhibition has shown only temporary and unsatisfactory effects.  
TNF-α inhibition was achieved via adalimumab, which is a fully human 
monoclonal antibody against TNF-α. However, that study also failed to result in 
significant symptom improvement over 12 weeks, although investigators examined no 
new erosion eruptions after inhibitor administration. Β-NGF is a major chronic pain 
mediator in inflammatory diseases, thus antagonizing it via humanized monoclonal 
antibodies like tanezumub have shown to decrease pain in OA patients. However, this 
clinical trial was terminated by the FDA after a few patients experienced a rapid disease 
progression resulting in immediate joint arthroplasties
74
.  
There have only been two published studies of growth factor intra-articular 
injections to date. One study was performed with bone morphogenetic protein 7 (BMP-7) 
and the other with fibroblast growth factor 18 (FGF-18).  Both resulted in general trend 
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improvements, but nothing clinically relevant. Concerns with local growth factor 
administration are increased potential risk for osteophyte formation as well as systematic 
diffusion of the doses could negatively affect distant tissue
74
. Although there have mixed 
results with the biological treatment of OA, there is still reason to believe that a multiple 
pathological progression mechanism of action solution could exist within the realm of 
biologics.  
Unfortunately, biologics are subjected to similarly difficult regulatory pathways 
as stem cell therapies and that could prove difficult in getting a product to market in a 
timely manner
70,71
.  An advantage to being classified as a medical device is a less 
extensive FDA approval pathway, which could aid such devices that are able to produce 
an intra-articular products in being able to positively affect the consumer population 




AUTOLOGOUS PROTEIN SOLUTION (APS) 
One of the caveats involved in intra-articular injections is the possibility of 
prompt elimination of the therapeutic from the joint space via the lymphatic system. 
Perhaps something with viable cellular component would be more beneficial as it could 
have immediate affects due to anti-inflammatory profile and long term affects as the cells 
could interact and bind with the native joint tissue. Zimmer Biomet has created a device 
that separates whole blood into a product called APS, which is a point-of-care therapy 
that contains high concentrations of anti-inflammatory cytokines and anabolic growth 
factors as well as viable white blood cells and platelets. APS is created via a two device 
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system where 60 mLs of anti-coagulated whole blood via a citrate is centrifuged in a 
cylindrical tube that contains a buoy attenuated to the density of red blood cells (RBCs). 
After centrifugation, the whole blood is separated into a RBC pack, platelet-poor plasma, 
and cell concentrate. The cell concentrate consists of the traditional buffy coat layer as 
well as a small amount of RBCs suspended in approximately 6 mLs of plasma.  
This PRP is then concentrated further by centrifuging another cylindrical tube 
filled by absorptive polyacrylamide beads. After centrifugation, the remaining solution is 
a concentrated version of PRP, which produces approximately 2 mLs of APS. Previous 
pilot studies have shown that APS can inhibit inflammatory IL-1β and TNF-α responses 
in monocytes and chondrocytes
76
. APS has also demonstrated an ability to protect bovine 





OA is a complex etiology that affects millions of people worldwide, causing them 
pain, increasing disability, and reduced quality of life. A disease modifying treatment is 
needed to reduce pain and increase joint mobility to prolong patients’ use of their own 
joint in order to reduce the chances of traumatizing revision surgery. The pathology of 
OA includes the overall disruption of cartilage homeostasis by inducing a catabolic shift 
driven by a complex mixture of inflammatory cytokines, namely IL-1β and TNF-α. These 
cytokines works synergistically to inflame the joint environment and ultimately destroy 
the cartilage matrix. 
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 The pathological progression includes all other tissues in the joint as close 
proximity exposes the tissue to similar inflammatory profiles
74
. The destructive cues 
given from the cartilage work in a feed-forward pathway with the synovium to ensure 
each other’s demise. The cartilage matrix debris in the synovial fluid aid in further 
inflaming the synovium, where the macrophages express a pro-inflammatory phenotype 
and release more inflammatory and matrix degrading mediators
74
. This pathology has 
multiple inflammatory induction pathways that need to be addressed if a disease 
modifying treatment is to be successful in treating OA. The most feasible route of 
conduction would be through the use of biologics, especially those that can alter both IL-




METHODS AND MATERIALS 
 
METHODS AND MATERIALS IN SUPPORT OF AIM 1: 
HUMAN OA CARTILAGE BIOPSY SAMPLE HARVEST AND CULTURING 
CONDITIONS 
All OA cartilage tissue samples were obtained from patients undergoing knee 
replacement surgery by the same surgeon via informed consent under an IRB (Greenville 
Health System) approved protocol (Pro00039016). Cartilage samples were collected in a 
sterile specimen container with approximately 70 mLs of 2% antibiotic/antimitotic 
(Ab/Am) culturing media and transported to The Laboratory of Orthopaedic Tissue 
Regeneration & Orthobiologics within 1 hour of harvest. Culture media consisted of 
Dulbecco’s Modified Eagle’s Medium (DMEM – 1 g/L glucose) (Gibco, 11885-084) 
containing 1% insulin-transferrin-selenium (ITS) (Life Technologies, 41400045), 50 nM 
ascorbate-2-phosphate (Life Technologies, 59-990-141), and 1% Ab/Am.  
Within a cell culture hood under aseptic conditions, full thickness cartilage 
biopsies (avoiding the calcified cartilage layer and subchondral bone) were taken after 
rinsing the tissue in culture media containing 2% Ab/Am and placed in a 20 mm plastic 
sterile petri dish with culture media containing 2% Ab/Am (Figure 4.1). All tissue 
biopsies were taken using a 6 mm diameter sterile biopsy (Miltex Instrument Co, 33-36) 
and sterile scalpel. The cartilage samples were placed in the bottom well of a 12 well 
trans-well plate fitted with 0.4 μm trans-well insert (Corning, 3460) with 1.5 mL of 
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culture media and placed in a humidified incubator at 37°C and 5% carbon dioxide. The 
culturing media was changed every third day of a 15 day total culture duration.  
 
Figure 4.1: Cartilage explant biopsy collection flowchart where the cartilage tissue sample undergoes A) general 
inspection with a close up view in order to see the primary defect B) 6mm biopsy is pressed into tissue around the 
primary defect, C) a scalpel is used to simultaneously trace and pry the cartilage sample from the femoral condyle, D) 
the upper image focuses on the quality of explant biopsy that was taken and the lower images focuses on the void left 
on the femoral condyle where all cartilage layers have been removed, E) multiple explant biopsies are taken and stored 
in 2% Ab/Am culture media, F) individual explants are placed in the bottom of a 12 well trans-well plate with 1% 
Ab/Am culture media. 
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Figure 4.2: Aim 1 analyses flowchart depicts the study overview and outline of the analyses associated with Aim 1. 
 
SAMPLE PREPARATION FOR HISTOLOGICAL, VIABILITY, AND 
BIOCHEMCIAL EVALUATION 
Each donor had one cartilage sample collected for the appropriate collection time 
points laid out in the flowchart (Figure 4.2). During sample collection, cartilage samples 
were cut into two pieces for their respective analysis. 
At the respective tissue collection time points within the 15 day study duration, 
tissue samples were cut and placed in tubes representing their individual tissue analyses. 
The samples collected for GAG content analysis were frozen at -80°C immediately after 
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collection while the sample used for viability analysis via LIVE/DEAD staining was 
placed in 1 mL of culturing media until the sample could be moved into staining solution. 
 
SEMI-QUANTITATIVE LIVE/DEAD VIABILITY ANALYSIS 
The LIVE/DEAD staining solution was prepared via the manufacture’s 
instruction (Biotium, 30002) and samples (n=3/time point) (Figure 4.2) were placed in 
~400 µL of staining solution for 45 minutes before imaging.  Three images per cartilage 
sample were taken at 200x magnification under a fluorescent microscope where cell 
viability was calculated according to Equation 1. All cell viability assessments were 
performed on 3 replications per tissue sample and all images were counted manually by a 
blinded observer.  
 
 
HISTOLOGY SAMPLE PREPARATION 
After the tissue samples were imaged for the LIVE/DEAD stain, they were 
immediately placed into 10% neutral buffered formalin (NBF).  All tissue samples 
remained in NBF for a minimum of 24 hours before the cartilage samples were placed in 
decalcifying solution, Immunocal, (Decal Company, 1414-1) for 36 hours before being 
processed. This time was confirmed by a turbidity test. The turbidity test was performed 
by mixing equal parts working decalcifying solution, 5% Ammonium hydroxide (VWR 
Scientific, BDH3868-1), and 5% Ammonium oxalate (PolyScientific R&D Corp., S2337-
16OZ) and allowing the solution to stand overnight. Decalcification is completed when 
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there is no observed precipitate within the solution. After cartilage tissue samples were 




Alcian Blue (Sigma, A3157-10G) staining was performed on rehydrated cartilage 
sections (n=3/time point) (Figure 4.2) by mordanting in 3% aqueous acetic acid prior to 
room temperature incubation of 1% Alcian Blue for 15 minutes. After sections are 
washed in running water for 10 minutes and then rinsed in distilled water, they are briefly 
incubated in 0.1% Nuclear Fast Red (Poly Scientific R&D Corp, S248-16OZ) for 7 
minutes before dehydration and imaging of cationic GAG content can take place.  
 
IMAGING 
Imaging of all histological samples was completed on a Vert.A1 Zeiss 
microscope. All histological samples were imaged in triple replication (three separate 
images per tissue sample) at a constant magnification before individual analysis of 
relative GAG content from a blinded observer. 
 
DIMETHYL METHYLENE BLUE ASSAY (DMMB) 
The portions of cartilage samples dedicated to GAG content analysis were 
lyophilized and digested in order to undergo a DMMB assay (n=3/ time point) (Figure 
4.2). Lyophilized tissues were digested in 125μg/mL papain in PBE Buffer at pH 7.5 at 
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65°C for 24 hours. Briefly, 200 μL of DMMB reagent (46 μg DMMB (Sigma, 341088-
1G), 40 mM Glycine, 40 mM NaCl, pH 3.0) was added to 50 μL of sample. The cartilage 
GAG content was calculated from a standard curve developed from a known 
concentration of chondroitin-6-sulfate (Sigma, C4384-5G) and read at 525 nm. 
 
LACTATE DEHYDROGENASE (LDH) 
Extracellular LDH content is a marker of cell injury and therefore LDH was 
analyzed as a secondary assessment of cell viability on media samples (n=3/ time point) 
(Figure 4.2). Comparisons were made to the media of a positive cell death control 
cartilage biopsy generated by 3 freeze/thaw cycles in liquid nitrogen. LDH kits were used 
on culture media according to manufacturer’s instruction (Pierce, 88954).  
 
STATISTICAL ANALYSIS 
All results are reported as average ± standard error of the mean (SEM). Statistical 
differences between samples were determined via a one-way analysis of variance 
(ANOVA) in JMP software.   
 
METHODS AND MATERIALS IN SUPPORT OF AIM 2: 
HUMAN BLOOD SAMPLE COLLECTION AND PROCESSING 
Human whole blood samples were obtained from patients undergoing knee 
replacement surgery by the same surgeon via informed consent under an IRB (Greenville 
Health System) approved protocol (Pro00039016). Donor blood was collected at least 2 
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weeks prior to surgery. A 60 mL luer lock syringe was pre-loaded with 5 mL of 
Anticoagulant Citrate Dextrose Solution-A (ACD-A) (CitraLabs, 9332). During blood 
collection, the phlebotomist tilted the 60 mL syringe in order to mix the anticoagulant as 
the 55 mL of whole blood was collected. Anticoagulated blood was processed via 
Zimmer Biomet’s nStride Autologous Protein Solution kit within a half hour of blood 
collection. Upon final processing steps, the APS was collected in 5 mL capped containers 
and frozen at -80°C.  
 
APS LEACHING PROFILE STUDY CULTURE CONDITIONS 
Each APS donor was plated with 250 μLs of APS plus 250 μLs of 1% Ab/Am 
culture media into 4 inserts of a 0.4 μm 12 well trans-well plate with 1.5 mL of 1% 
Ab/Am culture media in each of the bottom wells. The media from the wells were 
collected from each well at day 1, 2, 3, and 6 respectively with a media change occurring 
at day 3 (representing a typical media change cycle had there been tissue present in the 
culture). A media sample was taken of the stock culturing media as a negative control. 




Figure 4.3: Aim 2 analyses flowchart depicts the study overview and outline of analyses associated with Aim 2. 
 
ELISA  
Media samples taken at collection time points (n=3/ time point) (Figure 4.3) were 
subjected to ELISA analysis according to manufacturer’s instructions (R&D systems). 
The cytokine kits measured IL-1β (DLB50), TNF-α (DTA00C), IL-1ra (DRA00B), 
sTNF-RI (DRT100), and sTNF-RII (DRT200) concentrations. Briefly, 100 μL or 200 μL 
of sample or reconstituted standard are added to the pre-coated 96 well plates to incubate 
at room temperature for 2 hours. After thorough washing, 200 μL of conjugate cytokine 
are added to the wells and incubated at room temperature for 1 hour. After another 
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thorough washing, 200 μL of substrate solution is added to incubate at room temperature 
for 20 minutes before 50 μL of stop solution is added and the plates are read at 450nm 
with wavelength correction set to 540 nm or 570 nm.  
 
STATISTICAL ANALYSIS 
All results are reported as average ± standard error of the mean (SEM). Statistical 
differences between samples were determined via a one-way analysis of variance 
(ANOVA) in JMP software.   
 
METHODS AND MATERIALS IN SUPPORT OF AIM 3: 
HUMAN OA CARTILAGE AND SYNOVIUM BIOPSY SAMPLE HARVEST AND 
CULTURING CONDITIONS 
All OA cartilage and synovium tissue samples were obtained from patients 
undergoing knee replacement surgery by the same surgeon via informed consent under an 
IRB (Greenville Health System) approved protocol (Pro00039016). Cartilage and 
synovium samples were collected in a sterile specimen container with approximately 70 
mLs of 2% antibiotic/antimitotic (Ab/Am) culturing media and transported to The 
Laboratory of Orthopaedic Tissue Regeneration & Orthobiologics within 1 hour of 
harvest. Culture media consisted of Dulbecco’s Modified Eagle’s Medium (DMEM – 1 
g/L glucose) (Gibco, 11885-084) containing 1% insulin-transferrin-selenium (ITS) (Life 
Technologies, 41400045), 50 nM ascorbate-2-phosphate (Life Technologies, 59-990-
141), and 1% Ab/Am. Within a cell culture hood under aseptic conditions, cartilage tissue 
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samples were briefly rinsed in 2% Ab/Am culturing media before synovium biopsy 
samples were taken with a 6 mm biopsy punch (Miltex Instrument Co, 33-36) while 
avoiding fat deposits in order to obtain a pure synovium tissue biopsy.  Synovium 
biopsies were placed in a 20 mm plastic sterile petri dish with culture media containing 
2% Ab/Am until being plated in a well plate (Figure 4.4).  
 
Figure 4.4: Synovium explant biopsy collection flowchart in which the synovium tissue sample undergoes A) 
general inspection, B) a close up view in order to see macroscopic variations within the tissue, C) 6mm biopsy is 
pressed into tissue, D) a complete explant is taken by pressing and tracing the biopsy punch over the tissue, E) multiple 
explant biopsies are taken and stored in 2% Ab/Am culture media, F) individual explants are placed in the bottom of a 
12 well trans-well plate with 1% Ab/Am culture media. 
Full thickness cartilage biopsies were collected according to methods previously 
described in Aim 1. The cartilage and synovium samples were placed simultaneously as 
an explant co-culture in the bottom well of a 12 well trans-well plate fitted with 0.4 μm 
trans-well insert (Corning, 3460) with 1.5 mL of culture media and placed in a 
humidified incubator at 37°C and 5% carbon dioxide (Figure 4.5B). The media was 




Figure 4.5: Biopsies and culturing conditions. A) Cartilage (left) and synovium (right) samples with 6 mm biopsy 
samples taken from tissue. B) Magnified schematic view of a 12 well trans-well plate illustrating the relative position 
of APS, cartilage and synovial tissue samples (may want to label which is which in your pictures) for APS treated 
culture conditions. C) Magnified schematic view of a cartilage biopsy expanded and coded for which section of the 
biopsy is used for the respective analysis. D) Magnified schematic view of a synovium biopsy expanded and coded for 
which section of the biopsy is used for the respective analysis. 
 
HUMAN BLOOD COLLECTION, PROCESSING, AND DOSING CONDITIONS 
Patient matched blood was collected at least 2 weeks prior to cartilage and 
synovial tissue collection surgery. A 60 mL luer lock syringe was pre-loaded with 5 mL 
of Anticoagulant Citrate Dextrose Solution-A (ACD-A) (CitraLabs, 9332). During blood 
collection, the phlebotomist tilted the 60 mL syringe in order to mix the anticoagulant as 
the 55 mL of whole blood was collected. Anticoagulated blood was processed via 
Zimmer Biomet’s nStride Autologous Protein Solution kit within a half hour of blood 
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collection. Upon final processing steps, the APS was collected in 5 mL capped containers 
and frozen at -80°C.  
Following tissue collection and biopsy, the APS was thawed and 250 µL was 
added to the insert of the trans-well plate with 250 µL culturing media at day 0 for the 
APS treatment groups for single APS dose co-culture study (Figure 4.5B). All untreated 
OA control groups had 500 µL of culturing media added to the insert for the single APS 
dose co-culture study.  
 
Figure 4.6: Aim 3 analyses flowchart depicts the study overview and outline of analyses associated with Aim 3. 
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SAMPLE PREPARATION FOR VIABILITY, HISTOLOGICAL, CYTOKINE, AND 
BIOCHEMCIAL EVALUATION 
Each donor had one day 0 sample collected per tissue as well as an APS treated 
and untreated control samples per tissue collected at the appropriate collection time 
points (Figure 4.6). During sample collection, cartilage and synovium samples were cut 
into pieces according to Figure 4.5C&D to for their respective analysis. 
At the respective tissue collection time points within the 15 day study duration, all 
media in the well was collected in a 2 mL tube and frozen in -80°C immediately. The 
tissue samples were cut and placed in tubes respective of their individual tissue analyses. 
The samples collected for cytokine, GAG content, and DNA content analysis were frozen 
at -80°C immediately after collection while the sample used for viability analysis via 
LIVE/DEAD staining was placed in 1 mL of culturing media until the sample could be 
moved into staining solution. 
 
SEMI-QUANTITATIVE LIVE/DEAD VIABILITY ANALYSIS 
The LIVE/DEAD staining solution was prepared via the manufacture’s 
instruction (Biotium, 30002) and samples (n=4/time point/ condition/tissue) (Figure 4.6) 
were placed in ~400 µL of staining solution for 45 minutes before imaging.  Three 
images per cartilage and synovium sample were taken at 200x magnification under a 
fluorescent microscope where cell viability was calculated according to Equation 1. All 
cell viability assessments were performed on 3 replications per tissue sample and all 
images were counted manually by a blinded observer.  
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HISTOLOGY SAMPLE PREPARATION 
After the tissue samples were imaged for the LIVE/DEAD stain, they were 
immediately placed into 10% neutral buffered formalin (NBF).  All tissue samples 
remained in NBF for a minimum of 24 hours before the cartilage samples were placed in 
decalcifying solution, Immunocal, (Decal Company, 1414-1) for 36 hours before being 
processed. This time was confirmed with no observed particulates from a turbidity test. 
The turbidity test was performed by mixing equal parts working decalcifying solution, 
5% Ammonium hydroxide (VWR Scientific, BDH3868-1), and 5% Ammonium oxalate 
(PolyScientific R&D Corp., S2337-16OZ) and allowing the solution to stand overnight. 
Decalcification is completed when there are no observed participate within the solution. 
After cartilage tissue samples were processed, they were embedded, sectioned, and 
stained with Safranin-O/Fast Green in order to assess via the Osteoarthritis Research 
Society International (OARSI) scoring system. 
 
HISTOLOGICAL ANALYSIS 
Safranin-O/Fast Green staining was performed on rehydrated cartilage sections 
(n=4/ time point/ condition) (Figure 4.6) by differentiation in 1% acid alcohol for 3 
seconds prior to room temperature incubation in 0.02% Fast Green (Sigma, F7258-25G) 
for 2.5 minutes. After a brief, 30 second incubation in 1% acetic acid, sections were 
stained with 1% Safranin-O (Sigma, S2255-25G) for 15 minutes before dehydration and 
OARSI grading was determined.  
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OARSI scores of the Safranin-O/Fast Green cartilage samples were analyzed by 
three images taken at 50x in order to capture the entire span of the 6 mm section with 
minimal overlap (Figure 4.7). Each image was then assessed via the guidelines described 
in Pritzker et al where surface fibrillation and volume of cationic proteoglycan content 
are the primary grading focus
77
. OARSI scoring is unique in that it not only takes into 
account the severity or the progression of OA into the tissue but also the stage, or 
horizontal extent of the disease progression. Therefore an OARSI score (Equation 2) 
consists of both grade and stage or severity and extent. A blinded observer OARSI scored 
the three images per sample. The OARSI scores of the three images are averaged to 
generate an overall OARSI score of the cartilage sample to be compared to others. 
 
Figure 4.7: OARSI imaging guide of Safranin-O/ Fast Green stained cartilage samples where each colored square 






Evidence for chondrocyte proliferation was analyzed by ki-67 
immunohistochemistry (IHC) on paraffin embedded, 5μm cartilage histology sections 
(n=4/ time point/ condition) (Figure 4.6). Samples were deparafinized and rehydrated 
before antigen retrieval in 10 μM citric acid for 20 minutes at 90°C. Slides were rinsed 
twice in TBS for 5 minutes, permeabilized with 0.025% Triton X-100 (Fisher 
Scientific,BP151-500), blocked for non-specific binding with normal serum, and blocked 
for endogenous peroxidases with a solution of 0.3% hydrogen peroxidase in 0.3% normal 
serum (Vector Laboratories, Inc., S2000). Primary antibody (rabbit anti-ki-67 in a 
5μg/mL dilution) (Abcam, ab15580) was applied to all experimental sections at room 
temperature for 2 hours before thorough rinsing and a 30 minute room temperature 
incubation of secondary biotinylated antibody and avidin biotin complex according to 
manufacturer’s instruction (Vectastain ABC Elite Rabbit IgG, Vector Laboratories, Inc., 
PK-6101). Visualization of antibody was accomplished via staining with a DAB substrate 
kit (Vector Laboratories, Inc., SK4100) before a 30 second counterstain of 50% diluted 
hematoxylin. Negative controls maintained as secondary sections on the slides that did 
not receive primary antibody, but TBS during the primary antibody incubation step.  
All ki-67 staining was analyzed by imaging the slides at 50x to locate the areas of 
higher cell density within a sample in order to uniformly increase the probability of 
visualizing positive staining. Once the area of highest cell density was located, 3 images 
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taken at 200x were manually counted by a blinded observer and a percent of positive ki-




Imaging of all histological samples was completed on a Vert.A1 Zeiss 
microscope. All histological samples were imaged as three replicative images at a 
constant magnification before undergoing their individual assessments from a blinded 
observer. 
 
DIMETHYL METHYLENE BLUE ASSAY (DMMB) 
The portions of cartilage samples dedicated to GAG content analysis were 
lyophilized and digested in order to undergo a DMMB assay (n=4/ time point/ condition) 
(Figure 4.6). Lyophilized tissues were digested in 125μg/mL papain in PBE Buffer at pH 
7.5 at 65°C for 24 hours. Briefly, 200 μL of DMMB reagent (46 μg DMMB (Sigma, 
341088-1G), 40 mM Glycine, 40 mM NaCl, pH 3.0) was added to 50 μL of sample. The 
cartilage GAG content was calculated from a standard curve developed from a known 






 Cartilage samples (n=4/ time point/ condition) were lyophilized and digested in 
125μg/mL papain in PBE Buffer at pH 7.5 at 65°C for 24 hours. Digested cartilage 
samples were analyzed with a Quanti-iT Picogreen dsDNA Assay Kit according to 
manufacturer’s instruction (Life Technologies, P7589) Briefly, 100 μL of Picogreen 
reagent was added to 100 μLs of unknown samples and standards. The cartilage DNA 
content was calculated from a standard curve developed from known dsDNA content. 
Samples were incubated at room temperature for 5 minutes and read on a fluorescent 
plate reader at 480 nm (excitation) and 520 nm (emission). 
 
ELISA SAMPLE PREPARATION AND ANALYSIS 
Cartilage and synovium tissue homogenates were created by placing tissue 
samples in liquid nitrogen for approximately 1 minute and then pulverizing the flash 
frozen tissue with a biopulverizer (BioSpec, 59014N). The pulverized tissue was placed 
in a modified 50 mL conical tube and homogenized via a stainless stain, 7 mm 
homogenizer (Kinematica, 11030031) in a solution of 1% protease inhibitor cocktail 
(Sigma, P8340-5ML) in T-Per® Tissue Protein Extraction Reagent (Thermo 
Scientific,78510) at a gradually increased high speed for approximately 30 seconds. The 
volume of TPer® solution used was in accordance to manufacturer’s instruction given a 
sample’s tissue mass. Homogenized tissue samples were then centrifuged for 15 minutes 
at 12000 xg at 13°C and the supernatant was collected. The supernatant was then 
subjected to ELISA analysis according to manufacturer’s instructions (R & D Systems). 
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Media samples and tissue homogenate samples (n=4/ time point/ condition/ 
sample medium) (Figure 4.6) were subjected to ELISA analysis according to 
manufacturer’s instructions (R&D systems). The cytokine kits measured IL-1β (DLB50), 
TNF-α (DTA00C), IL-1ra (DRA00B), sTNF-RI (DRT100), and sTNF-RII (DRT200) 
concentrations. Briefly, 100 μL or 200 μL of sample or reconstituted standard are added 
to the pre-coated 96 well plates to incubate at room temperature for 2 hours. After 
thorough washing, 200 μL of conjugate cytokine are added to the wells and incubated at 
room temperature for 1 hour. After another thorough washing, 200 μL of substrate 
solution is added to incubate at room temperature for 20 minutes before 50 μL of stop 
solution is added and the plates are read at 450nm with wavelength correction set to 540 
nm or 570 nm.  
 
STATISTICAL ANALYSIS 
All results are reported as average ± standard error of the mean (SEM). Statistical 
differences between samples were determined via a one-way analysis of variance 
(ANOVA) in JMP software.   
 
METHODS AND MATERIALS IN SUPPORT OF AIM 4: 
HUMAN OA TISSUE AND BLOOD COLLECTION AND PROCESSING  
All cartilage and synovium tissue was collected according to the previously 
described in Aim 3. APS was collected and processed according to methods previously 
described in Aim 3.  
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HUMAN OA CARTILAGE AND SYNVOIUM CULTURING CONDITIONS 
Following tissue collection and biopsy, the tissue samples were plated according 
to the same conditions previously described in Aim 3 where APS was thawed and 250 µL 
was added to the insert of the trans-well plate with 250 µL of culturing media for the APS 
treatment group (Figure 4.5B). APS was added at day 0 and at day 6 (with a new sterile 
insert) for the double APS dose co-culture study.  All untreated OA control groups had 
500 µL of culturing media added to the insert for the double APS dose co-culture study. 
 
Figure 4.8: Aim 4 analyses flowchart depicts the study overview and outline of analyses associated with Aim 4. 
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SAMPLE PREPARATION FOR VIABILITY, HISTOLOGICAL, CYTOKINE, AND 
BIOCHEMCIAL EVALUATION 
Each donor had one day 0 sample collected per tissue as well as an APS treated 
and untreated control samples per tissue collected at the appropriate collection time 
points (Figure 4.8). During sample collection, cartilage and synovium samples were cut 
into pieces according to Figure 4.5C&D to for their respective analysis. 
At the respective tissue collection time points within the 15 day study duration, all 
media in the well was collected in a 2 mL tube and frozen in -80°C immediately. The 
tissue samples were cut and placed in tubes respective of their individual tissue analyses. 
The samples collected for cytokine, GAG content, and DNA content analysis were frozen 
at -80°C immediately after collection while the sample used for viability analysis via 
LIVE/DEAD staining was placed in 1 mL of culturing media until the sample could be 
moved into staining solution. 
 
SEMI-QUANTITATIVE LIVE/DEAD VIABILITY ANALYSIS 
The LIVE/DEAD staining solution was prepared via the manufacture’s 
instruction (Biotium, 30002) and samples (n=4/ time point/ condition/ tissue) (Figure 
4.8) were placed in ~400 µL of staining solution for 45 minutes before imaging.  Three 
images per cartilage and synovium sample were taken at 200x magnification under a 
fluorescent microscope where cell viability was calculated according to Equation 1. All 
cell viability assessments were performed on 3 replications per tissue sample and all 
images were counted manually by a blinded observer.  
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HISTOLOGY SAMPLE PREPARATION 
After the tissue samples were imaged for the LIVE/DEAD stain, they were 
immediately placed into 10% neutral buffered formalin (NBF).  All tissue samples 
remained in NBF for a minimum of 24 hours before the cartilage samples were placed in 
decalcifying solution, Immunocal, (Decal Company, 1414-1) for 36 hours before being 
processed. This time was confirmed with no observed particulates from a turbidity test. 
The turbidity test was performed by mixing equal parts working decalcifying solution, 
5% Ammonium hydroxide (VWR Scientific, BDH3868-1), and 5% Ammonium oxalate 
(PolyScientific R&D Corp., S2337-16OZ) and allowing the solution to stand overnight. 
Decalcification is completed when there are no observed participate within the solution. 
After cartilage tissue samples were processed, they were embedded, sectioned, and 
stained with Safranin-O/Fast Green in order to assess via the Osteoarthritis Research 
Society International (OARSI) scoring system. 
 
HISTOLOGICAL ANALYSIS 
Safranin-O/Fast Green staining was performed on rehydrated cartilage sections 
(n=4/ time point/ condition) (Figure 4.8) by differentiation in 1% acid alcohol for 3 
seconds prior to room temperature incubation in 0.02% Fast Green (Sigma, F7258-25G) 
for 2.5 minutes. After a brief, 30 second incubation in 1% acetic acid, sections were 
stained with 1% Safranin-O (Sigma, S2255-25G) for 15 minutes before dehydration and 
OARSI grading was determined.  
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OARSI scores of the Safranin-O/Fast Green cartilage samples were analyzed by 
three images taken at 50x in order to capture the entire span of the 6 mm section with 
minimal overlap (Figure 4.7). Each image was then assessed via the guidelines described 
in Pritzker et al where surface fibrillation and volume of cationic proteoglycan content 
are the primary grading focus
77
. OARSI scoring is unique in that it not only takes into 
account the severity or the progression of OA into the tissue but also the stage, or 
horizontal extent of the disease progression. Therefore an OARSI score (Equation 2) 
consists of both grade and stage or severity and extent. A blinded observer OARSI scored 
the three images per sample. The OARSI scores of the three images are averaged to 
generate an overall OARSI score of the cartilage sample to be compared to others. 
 
IMMUNOHISTOCHEMICAL ANALYSIS 
Evidence for chondrocyte proliferation was analyzed by ki-67 
immunohistochemistry (IHC) on paraffin embedded, 5μm cartilage histology sections 
(n=4/time point/ condition) (Figure 4.8). Samples were deparafinized and rehydrated 
before antigen retrieval in 10 μM citric acid for 20 minutes at 90°C. Slides were rinsed 
twice in TBS for 5 minutes, permeabilized with 0.025% Triton X-100 (Fisher 
Scientific,BP151-500), blocked for non-specific binding with normal serum, and blocked 
for endogenous peroxidases with a solution of 0.3% hydrogen peroxidase in 0.3% normal 
serum (Vector Laboratories, Inc., S2000). Primary antibody (rabbit anti-ki-67 in a 
5μg/mL dilution) (Abcam, ab15580) was applied to all experimental sections at room 
temperature for 2 hours before thorough rinsing and a 30 minute room temperature 
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incubation of secondary biotinylated antibody and avidin biotin complex according to 
manufacturer’s instruction (Vectastain ABC Elite Rabbit IgG, Vector Laboratories, Inc., 
PK-6101). Visualization of antibody was accomplished via staining with a DAB substrate 
kit (Vector Laboratories, Inc., SK4100) before a 30 second counterstain of 50% diluted 
hematoxylin. Negative controls maintained as secondary sections on the slides that did 
not receive primary antibody, but TBS during the primary antibody incubation step.  
All ki-67 staining was analyzed by imaging the slides at 50x to locate the areas of 
higher cell density within a sample in order to uniformly increase the probability of 
visualizing positive staining. Once the area of highest cell density was located, 3 images 
taken at 200x were manually counted by a blinded observer and a percent of positive ki-
67 stained cells was calculated per image (Equation 3).  
 
IMAGING 
Imaging of all histological samples was completed on a Vert.A1 Zeiss 
microscope. All histological samples were imaged as three replicative images at a 
constant magnification before undergoing their individual assessments from a blinded 
observer. 
 
DIMETHYL METHYLENE BLUE ASSAY (DMMB) 
The portions of cartilage samples dedicated to GAG content analysis were 
lyophilized and digested in order to undergo a DMMB assay (n=4/time point/ condition) 
(Figure 4.8). Lyophilized tissues were digested in 125μg/mL papain in PBE Buffer at pH 
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7.5 at 65°C for 24 hours. Briefly, 200 μL of DMMB reagent (46 μg DMMB (Sigma, 
341088-1G), 40 mM Glycine, 40 mM NaCl, pH 3.0) was added to 50 μL of sample. The 
cartilage GAG content was calculated from a standard curve developed from a known 
concentration of chondroitin-6-sulfate (Sigma, C4384-5G) and read at 525 nm. 
 
PICOGREEN ASSAY 
 Cartilage samples (n=4/ time point/ condition) were lyophilized and digested in 
125μg/mL papain in PBE Buffer at pH 7.5 at 65°C for 24 hours. Digested cartilage 
samples were analyzed with a Quanti-iT Picogreen dsDNA Assay Kit according to 
manufacturer’s instruction (Life Technologies, P7589) Briefly, 100 μL of Picogreen 
reagent was added to 100 μLs of unknown samples and standards. The cartilage DNA 
content was calculated from a standard curve developed from known dsDNA content. 
Samples were incubated at room temperature for 5 minutes and read on a fluorescent 
plate reader at 480 nm (excitation) and 520 nm (emission). 
 
ELISA SAMPLE PREPARATION AND ANALYSIS 
Cartilage and synovium tissue homogenates were created by placing tissue 
samples in liquid nitrogen for approximately 1 minute and then pulverizing the flash 
frozen tissue with a biopulverizer (BioSpec, 59014N). The pulverized tissue was placed 
in a modified 50 mL conical tube and homogenized via a stainless stain, 7 mm 
homogenizer (Kinematica, 11030031) in a solution of 1% protease inhibitor cocktail 
(Sigma, P8340-5ML) in T-Per® Tissue Protein Extraction Reagent (Thermo 
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Scientific,78510) at a gradually increased high speed for approximately 30 seconds. The 
volume of TPer® solution used was in accordance to manufacturer’s instruction given a 
sample’s tissue mass. Homogenized tissue samples were then centrifuged for 15 minutes 
at 12000 xg at 13°C and the supernatant was collected. The supernatant was then 
subjected to ELISA analysis according to manufacturer’s instructions (R & D Systems). 
Media samples and tissue homogenate samples (n=4/ time point/ condition/ 
sample medium) (Figure 4.8) were subjected to ELISA analysis according to 
manufacturer’s instructions (R&D systems). The cytokine kits measured IL-1β (DLB50), 
TNF-α (DTA00C), IL-1ra (DRA00B), sTNF-RI (DRT100), and sTNF-RII (DRT200) 
concentrations. Briefly, 100 μL or 200 μL of sample or reconstituted standard are added 
to the pre-coated 96 well plates to incubate at room temperature for 2 hours. After 
thorough washing, 200 μL of conjugate cytokine are added to the wells and incubated at 
room temperature for 1 hour. After another thorough washing, 200 μL of substrate 
solution is added to incubate at room temperature for 20 minutes before 50 μL of stop 
solution is added and the plates are read at 450nm with wavelength correction set to 540 
nm or 570 nm.  
 
STATISTICAL ANALYSIS 
All results are reported as average ± standard error of the mean (SEM). Statistical 
differences between samples were determined via a one-way analysis of variance 









 The generation of a model that mimics natural OA progression while 
concomitantly maintaining cell viability is fundamental for the evaluation of therapies 
targeting OA modification. Thus, the first step of the project was establishing an in vitro 
model that can maintain viable cells and can demonstrate matrix degradation reminiscent 
of OA in vitro. During the initial study, only cartilage biopsy samples were taken from 3 
late stage OA patients analyzed via histological and biochemical assessments after a 15 
day culture period. Histological samples were evaluated via Alcian Blue/ Nuclear Fast 
Red staining for variations in cellular and extracellular matrix similar to in vivo OA 
progression. A LIVE/DEAD assay and lactate dehydrogenase assay were performed on 
the cartilage tissue to respectfully semi-quantitatively and quantitatively determine mean 
chondrocyte viability within the OA cartilage biopsy over the culture duration. A DMMB 
assay quantitatively evaluated GAG content in late stage OA cartilage biopsies with 
respect to time. This study aims to demonstrate the generation of a viable in vitro model 







OA CARTILAGE BIOPSY VIABILITY 
OA cartilage biopsy samples were obtained from the femoral condyles of 3 
patients where the approximate severity of OA had progressed to a Kellgren-Lawrence 
stage 4. Semi-quantitative LIVE/DEAD evaluation of OA cartilage explant biopsy 
samples (n= 3/ time point) obtained at day 3, 6, and 15 indicate that chondrocyte viability 
was 84.49 ± 5.92, 89.61 ± 2.75 and 84.60 ± 6.19, respectively (Figure 5.1). Live 
chondrocytes were observed throughout the entire thickness (from superficial layer 
through the transitional zone) of the cartilage biopsy samples. No significant differences 
in chondrocyte viability between any of the time-points evaluated were noted. All images 
were randomly captured throughout the cartilage sections, thus no one cartilage zone was 
analyzed, but OA indicative clustering was observed in the majority of images.  
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Figure 5.1: Chondrocyte viability. A) Graphical representation of percent cell viability within OA cartilage explant 
biopsy cultures obtained from LIVE/DEAD imaging. Representative LIVE/DEAD images obtained at B) Day 3, C) 
Day 6 and D) Day 15, respectively. Live cells = green, dead cells = red. Original total magnification of images is 200X. 
 
LDH ANALYSIS 
Mean LDH activity levels measured in media collected from biopsy samples 
(n=3/ time point) at day 0, 3, 6, 9 and 15 (Figure 5.2) were 39.44% ± 14.25%, 46.56% ± 
5.97%, 16.33% ± 11.26%, 21.39% ± 12.35% and 9.63% ± 4.14%, respectively compared 
to the positive control for cell death samples (n = 3 samples subjected to 3 snap freeze – 
thaw cycles). Percent LDH activity at all time-points was significantly lower than the 
positive death control. Additionally, the percent LDH activity at day 6, 9 and 15 were not 
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significantly different from each other, but were significantly lower compared to the 
activity at day 0 and 3. One-hundred percent cell death in the positive death control was 
confirmed with LIVE/DEAD staining (data not shown). Taken together with the 
LIVE/DEAD data, these results indicate that chondrocyte viability within the OA 
cartilage biopsy explants was maintained throughout the entire 15 day culture period and 
that cell death did not increase with time in culture. 
 
Figure 5.2: LDH activity in cartilage explants. Graphical representation of the relative percentage of lactate 







HISTOLOGICAL ASSESSMENT OF OA CARTILAGE EXPLANT BIOPSIES  
Initial histological evaluations of OA cartilage biopsy explants (Figure 5.3) 
stained with Alcian Blue (blue = glycosaminoglycan) and Nuclear Fast Red (pink = cell 
nuclei) illustrate a glycosaminoglycan-rich ECM containing round chondrocytes residing 
within lacunae (i.e. expected morphology for these cells). Variability in the relative 
intensity of ECM staining was observed between patients. Chondrocyte cloning was 
evident in all samples indicative of OA cartilage. It did appear that glycosaminoglycan 
staining intensity did decrease with time in culture and in some cases the superficial layer 
of OA cartilage explant biopsies had focal areas devoid of glycosaminoglycan by day 15. 
 
Figure 5.3: OA cartilage explant biopsies stained with Alcian Blue from A) the positive control for cell death and 
B) day 0, C) day 3, and D) day 6. Glycosaminoglycan (GAG) = blue, cell nuclei and ECM devoid of GAG = pink. 
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GAG CONTENT OF OA CARTILAGE EXPLANT BIOPSIES 
 A quantitative analysis of the GAG content collected at day 3, 6, and 15 indicates 
an average of 274.63 ± 38.86, 297.29 ± 64.5, and 234.24 ± 43.37 μg GAG/ mg dry 
weight, respectively, (Figure 5.4A) when GAG content is normalized to the lyophilized 
dry weights of the samples. GAG content normalized to dry weight demonstrated a 15% 
loss in GAG content from day 3 to 15. However, GAG content was also normalized to 
DNA content to compare and determine the most comprehensible graphical 
representation method. GAG content normalized to DNA content at day 3, 6, and 15 
shows an average of 1400.54 ± 207.42, 1694.96 ± 131.75, and 1353.26 ± 205.26 μg 
GAG/ μg DNA content, respectively (Figure 5.4B). GAG content normalized to DNA 
content demonstrated a 3% loss of GAG content from day 3 to 15.  
 
Figure 5.4: GAG content. A) Graphical representation of the average GAG content normalized to dry weight of OA 
cartilage samples. B) Graphical representation of the average GAG content normalized to cell DNA content.  
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DISCUSSION 
 This initial cartilage only culture study maintained cellular viability throughout 
the culture duration. Early in the culture duration there was an initial decrease in cell 
viability of the OA cartilage biopsies. The slight decrease in cell viability could be due to 
the trauma the biopsies undergo as they are removed from the femoral condyle. The 
slight increase and maintenance in cell viability seen throughout the remainder of the 
culture duration could then be due to the acclimation of the cartilage biopsies in the well 
plate environment. Future representations of cell viability in this thesis will be provided 
by a LIVE/DEAD assay. LDH is not a direct measure of cell viability and LDH results 
were not compared to a standard curve of a known cell death population.  
GAG loss is associated with the OA hallmark of cartilage matrix destruction
12,29
. 
The viable chondrocytes in the OA cartilage aid in the ECM degradation as the 
chondrocytes produce MMP-13 and ADAMTS
10,12
. In vivo OA cartilage ECM 
progressively degrades to severe late stage destruction that is commonly referred to as 
bone (femoral) on bone (tibial) contact. Both methods of normalizing the GAG content in 
OA cartilage explants resulted in moderate GAG loss over time, but not progressive 
enough to represent an in vivo model. Therefore, the initial OA human cartilage explant 






CARTILAGE AND SYNOVIUM CO-CULTURE MODEL 
This moderately OA progressive, cartilage only model lead to a pilot study (n=1) 
of simultaneously co-culturing human OA cartilage and synovium in a trans-well plate 
environment. The cartilage and synovium co-culture revealed promising matrix 
degradation indicative of in vivo OA progression. Therefore, I assisted a lab colleague in 
conducting a larger study of 15 donors where a human OA cartilage and synovium co-
culture model was verified to demonstrate key aspects of human OA.  
Briefly, 6 mm biopsies of human OA cartilage and synovium were collected using 
techniques described in Chapter 4 and placed in a 12 well trans-well plate with removable 
insert porosities of 3 μm. The cartilage biopsies were placed in the bottom of the well 
plate with 1.5 mL of culturing media and the synovium biopsies were placed in the 
removable inserts with 500 μL of culturing media. Tissue samples and media samples 
were collected at day 0 and 15 for viability, histological, and biochemical evaluations 
including an ELISA, hydroxyproline assay, and DMMB assay.  
The human OA co-culture maintained a statistically lower percent of chondrocyte 
viability compared to cartilage only cultures by day 15 (data not shown), however, there 
were still viable chondrocytes that aided in the progression of OA throughout the culture 
duration. The co-culture model also exhibited statistically increased cartilage fibrillation 
assessed via semi-quantitative histological OARSI scoring (data not shown) as compared 
to the cartilage only culture model.  
There was a 54% GAG reduction in cartilage samples co-cultured with synovium 
compared to 9% more GAG maintained in cartilage only cultures by day 15 (Figure 5.5). 
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This GAG reduction is statistically more progressive than our cartilage only culture 
model (p<0.05) and is more representative of gradual in vivo matrix degradation. 
Collagen leaching from cartilage is another indication of progressive matrix destruction. 
Co-cultured cartilage experienced a 50% increase in collagen leached into the media, 
while cartilage only cultures had a 33% decrease in collagen leached into the media 
(Figure 5.6).  This trend in collagen leaching was promising as previous studies have 
indicated that collagen leaching in OA cartilage does not typically peak until 4 weeks
78
. 
The GAG loss and increase in collagen leaching into the media were promising results 
indicative of a more progressive OA pathology than a simple OA cartilage explant 
culture.  
 
Figure 5.5: GAG content of co-culture and cartilage only cultures represented graphically where * indicates statistical 
difference (p<0.05) between culture condition groups and # indicates statistical difference (p<0.05) from day 0. 
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Figure 5.6: Media hydroxyproline content indicative of collagen leaching from co-culture and cartilage only 
cultures represented graphically. * indicates statistical difference (p<0.05) between culture condition groups. 
 The co-culture model maintained greater concentrations of pro-inflammatory 
cytokines and matrix degrading enzymes compared to cartilage only cultures. The co-
culture was able to maintain a detectable, physiologic pro-inflammatory milieu 
throughout the culture duration (Figure 5.7). OA synovial fluid concentrations of IL-1β 
and TNF-α are typically < 5.0 pg/ml and < 10 pg/ml, respectively7,56,59. Our co-culture 
model supports these physiologic ranges whereas chemically induce OA with 





Figure 5.7: Pro-inflammatory milieu concentration represented graphically where A) shows the IL-1β 
concentration, B) shows the TNF-α concentration, and C) shows the MMP-13 concentration in the media of the co-
culture and cartilage only culture models. * indicates a statistical difference between culture conditions (p<0.05).  
 
The cartilage and synovium function in a feed-forward process where they 
contribute to each other’s disease progression. The co-culture model exhibited the 
capability of modeling OA by degrading cartilage matrix with a gradual progression over 
time as well as maintaining an appropriate pro-inflammatory milieu and downstream 
matrix degrading enzymes for the culture duration. Thus, the co-culture model is an ideal 









Zimmer Biomet had previously characterized the pro- and anti-inflammatory 
mediator profiles of APS (Table 6.1). APS was found to have a 3.8 fold increase in the 
natural inhibitors of the primary pro-inflammatory cytokines involved in OA (IL-1β and 
TNF-α) compared to the patient matched whole blood of healthy individuals
8
. The APS 
kit’s ability to naturally increase the innate inhibitors of these synergistic pro-
inflammatory cytokines is thought to be a promising OA therapy
5,11
 However, the 
concentrations of the cytokine profile of APS while in co-culture was not known. The 
concentrations of pro and anti-inflammatory cytokines that the OA cartilage and 
synovium tissue is exposed to for the duration of the culture is necessary to later 
extrapolate the cytokine concentrations produced by the co-culture model (Aim 3 & 4). 
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Table 6.18: APS characterization of anabolic, pro-inflammatory, and anti-inflammatory cytokine concentrations 





 A quantitative analysis via ELISA was also performed on co-culture media 
samples (n=3/ time point) at day 1, 2, 3, and 6 where no tissue was present in the culture 
in order to determine the APS leaching profile that the tissue is exposed to during normal 
co-culture conditions. The same pro and anti-inflammatory cytokines were quantified in 
the APS leaching profile. The APS leaching profile of the media resulted in negligible 
concentrations of TNF-α and therefore was not presented. Average media IL-1β 
concentrations were 29.47 ± 23.74, 35.50 ± 28.54, 51.67 ± 41.31, and 19.87 ± 12.08 
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pg/ml for day 1, 2, 3, and 6 respectively. The raw donor values shown in Figure 6.1 
illustrate the general trends over the interpatient variability where concentrations peak at 
day 3.  
 
Figure 6.1: IL-1β APS leaching profile of leachate concentration represented graphically where general trends are 
followed for each patient and the average IL-1β concentration for all donors at day 6 is indicated by a dotted line. 
 The average sTNF-RI concentrations at day 1, 2, 3, and 6 were 252.37 ± 34.18, 
300.59 ± 35.59, 326.90 ± 34.58, and 126.10 ± 10.47 pg/ml respectively. The average 
sTNF-RII concentrations were 382.50 ± 45.08, 454.22 ± 66.74, 517.92 ± 57.35, and 
209.79 ± 30.12 pg/ml respectively. The average IL-1ra concentrations were 706.0 ± 
193.13, 417.33 ± 131.95, 274.33 ± 102.71, and 3.33 ± 8.21 pg/ml for days 1, 2, 3, and 6 
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respectively. Figure 6.2 shows all three anti-inflammatory cytokines as raw individual 
patient data to better illustrate the trends seen over the patient variability.  
 
Figure 6.2: Anti-inflammatory cytokine leaching profile of leachate concentration represented graphically where 
general trends are followed for each patient and the average cytokine concentration for all donors at day 6 is indicated 
by a dotted line for A) sTNF-RI, B) sTNF-RII, and C) IL-1ra. 
 
DISCUSSION 
The pro and anti-inflammatory cytokine concentrations of pure APS seen in Table 
6.1 are multiple folds higher than the day 1 leachate pro and anti-inflammatory cytokine 
concentrations. This considerable decrease in concentration could be due to the dilution 
of APS by the culturing media when it is placed in tissue culturing conditions. Dilution 
could also be effecting the relative concentration trends between the measured pro and 
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anti-inflammatory cytokines in pure APS and average leachate concentrations. According 
to the measured cytokine concentration trend in Table 6.1, IL-1ra had the highest 
concentration followed by sTNF-RII, sTNF-RI, and IL-1β, respectively, average leachate 
concentrations only followed that trend at day 1. However, Table 6.1 values were 
reported from a donor population of 10, while the APS leaching study assessed 3 donors. 
In Figure 6.1, patient 1 experienced supraphysiologic levels of IL-1β which could not be 
accounted for with our basic patient demographic documentation. This is a prime 
example of the large interpatient variability present in human studies and supports the 
need for larger donor populations when working with human tissue.  
The cytokine concentration profiles of APS leachate generally demonstrated a 
depletion of all measured cytokines by day 6. This gradual depletion in correlation with 
media changes suggests that the frequency of media changes is depleting the in vitro co-
culture model of APS cytokine concentrations. This decrease in cytokine exposure could 
ultimately decrease the probability of APS having an effect on an in vitro model. 
Therefore, investigating alterative dosing patterns of APS in the in vitro model could 
enhance the exposure of anti-inflammatory cytokine concentrations on OA tissue to 




AIM 3: TO ASSESS THE EFFICACY OF A SINGLE DOSE OF APS IN MITIGATING 
OA PROGRESSION IN VITRO 
 
INTRODUCTION 
 In order to establish a baseline effect of APS on a human OA cartilage and 
synovium co-culture, a single dose of APS in co-culture was evaluated by comparing cell 
viability, histological, and biochemical evaluations on tissue and media samples against 




 Chondrocyte viability was assessed via LIVE/DEAD staining of the OA cartilage 
tissue (n=4/time point/ condition). The average percentage of chondrocyte viability of the 
APS treated group for day 0, 6 and 15 were 96.08 ± 1.55, 80.42 ± 6.37, and 83.19 ± 
6.95%, respectively. The average percentage of chondrocyte viability for untreated OA 
control group at day 0, 6 and 15 were 96.08 ± 1.55, 82.87 ± 3.83, and 73.68 ± 10.60%, 
respectively (Figure 7.1). Replication images were randomly taken throughout the tissue 
in order to accurately represent the cartilage as a whole. There was observed chondrocyte 
clustering (indicative of OA cartilage) throughout the majority of chondrocyte viability 
images. A statistical decrease in chondrocyte viability was observed from day 0 to day 15 
in the untreated OA control group (p<0.05). Overall, chondrocyte viability is maintained 
in the APS treated group and untreated OA control throughout the co-culture period.  
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Figure 7.1: Chondrocyte viability represented graphically as a percentage of viable chondrocytes and representative 
images of OA cartilage tissue when co-cultured with OA synovium. # indicates a statistical difference from day 0 
(p<0.05). 
 Synovial cell viability was also assessed via LIVE/DEAD staining of the OA 
synovium tissue explants (n=4/ time point/ condition). The average percentage of viable 
synoviocytes of the APS treated group at day 0, 6, and 15 were 57.13 ± 18.30, 73.80 ± 
10.92, and 74.05 ± 12.28%, respectively. The average percentage of viable synoviocytes 
of the untreated OA control group at day 0, 6, and 15 were 57.12 ± 18.30, 59.67 ± 16.28, 
and 61.45 ± 14.41%, respectively. Synovial cell viability was maintained in the APS and 
untreated OA control synovium throughout the culture duration (Figure 7.2). Native 
fibroblastic synovial cells and synovial macrophages were both identified in a majority of 
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the synovial images by differences in cell morphology, as fibroblasts have more spindled 
shape and macrophages are larger and round. 
 
Figure 7.2: Synoviocyte viability represented graphically as a percentage of viable synovial cells and representative 
images of OA synovium tissue when co-cultured with OA cartilage.  
 
HISTOLOGICAL ANALYSIS 
 Upon histological assessment via OARSI scoring of the OA cartilage tissue (n=4/ 
time point/ condition), the APS treated and the untreated OA control cartilage tissue both 
maintained their OARSI score for the culture duration. The average OARSI scores for the 
APS treated cartilage at day 0, 6, and 15 were 6.38 ± 1.77, 11.22 ± 4.24, and 7.63 ± 2.27, 
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respectively. The average OARSI scores for the untreated OA control cartilage at day 0, 
6, and 15 were 6.38 ± 1.77, 9.33 ± 1.76, and 6.5± 2.67, respectively (Figure 7.3).  
 
Figure 7.3: OARSI scores presented graphically with representative images of cartilage samples depicting the effect 
of a single dose of APS on OA cartilage when in co-culture with OA synovium at day 15 and untreated OA cartilage 
controls at day 0 and 15. Red indicates proteoglycan rich ECM, while green indicates proteoglycan poor ECM. 
 
IMMUNOHISTOCHEMICAL ANALYSIS 
Evidence of chondrocyte proliferation was measured via ki-67 IHC on the 
cartilage tissue (n=4/ time point/ condition) and resulted in a general increasing 
proliferation trend throughout the culture time period among both APS treated and 
untreated OA control groups (Figure 7.4). The average percentage of cells stained 
positively for ki-67 in the APS treated group at day 0, 6, and 15 were 19. 05 ± 4.47, 27.12 
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± 3.01, and 31.14 ± 9.40%, respectively. The average percentage of positively stained 
cells in the non-treated OA control group at day 0, 6, and 15 were 19.05 ± 4.47, 27.38 ± 
2.10, and 37.41 ± 8.68%, respectively. Only the untreated OA control at day 15 was 
statistically greater than day 0 proliferation.  
 
Figure 7.4: Chondrocyte proliferation presented graphically as percentages of positively ki-67 stained cells in OA 
cartilage with representative images of cartilage samples depicting the effect of a single dose of APS on OA cartilage 
when in co-culture with OA synovium at day 15 and untreated OA cartilage controls at day 0 and 15. Black circles 
indicate positive brown staining and inlayed images in upper left corners are respective negative controls. # indicates 







 The quantitative GAG analysis of the OA cartilage samples (n=4/ time point/ 
condition) collected at day 0, 6, and 15 resulted in an average of 174.34 ± 35.17, 130.75 
± 6.41, and 142.63 ± 23.03 μg GAG/ mg dry weight for the APS treated samples 
respectively and 174.34 ± 35.17, 115.87 ± 12.96, and 139.36 ± 43.95 μg GAG/ mg dry 
weight for the untreated OA controls respectively (Figure 7.5).  There is a 20% loss of 
GAG in the OA control by day 15 and an 18% GAG loss in the APS treated group by day 
15.  
 
Figure 7.5: GAG content represented graphically as average GAG content normalized to dry weight of single dose 




 The DNA content of cartilage samples (n=4/ time point/ condition) was 
quantitatively analyzed and normalized to tissue dry weight at day 0, 6, and 15. The 
average DNA contents normalized to dry weight of the APS treated cartilage were 0.016 
± 0.03, 0.13 ± 0.01, and 0.16 ± 0.03 μg DNA/ mg dry weight for day 0, 6, and 15 
respectively. The average DNA contents normalized to dry weight of the untreated OA 
control cartilage were 0.16 ± 0.03, 0.22 ± 0.05, and 0.15 ± 0.02 μg DNA/ mg dry weight 
respectively (Figure 7.6).  
 
Figure 7.6: DNA content represented graphically as average DNA content normalized to tissue dry weight where 
single dosed APS cartilage in co-culture with OA synovium was compared to untreated OA control cartilage in co-




The quantitative cytokine analyses were completed on the cartilage and synovium 
tissue homogenates (n=4/ time point/ condition/ tissue) as well as the media (n=4/ time 
point/ condition) in order to establish the distribution of the prominent pro and anti-
inflammatory cytokines within the co-culture model. The pro-inflammatory cytokines 
measured were IL-1β and TNF-α. The average IL-1β concentration of the cartilage tissue 
homogenates of the APS treated group were 0.63 ± 0.10, 2.26 ± 1.55, and 0.57 ± 0.19 
pg/ml for day 0, 6, and 15 respectively. The average IL-1β concentration of the cartilage 
tissue homogenates untreated OA controls were 0.63 ± 0.10, 0.88 ± 0.48, and 0.85 ± 0.17 
pg/ml respectively (Figure 7.7A). Day 6 APS treated cartilage homogenate was had a 
statistically higher concentration compared to day 15 APS treated cartilage homogenate 
(p<0.05)  
The media taken from the APS co-culture had an average IL-1β concentration of 
0.0 ± 0.0, 14.82 ± 7.15, and 1.33 ± 0.55 pg/ml for day 0, 6, and 15 respectively. The 
average IL-1β concentration for the untreated OA control co-culture media was 0.0 ± 0.0, 
4.48 ± 2.71, and 0.17 ± 0.12 pg/ml respectively (Figure 7.7B). Day 6 APS treated co-
culture media was statistically greater than its respective control (p<0.05). Day 6 APS 
treated co-culture media was also statistically greater than day 0 and day 15 APS treated 
co-culture media (p<0.05).  
The average IL-1β concentration of the synovium tissue homogenate of the APS 
treated group was 1.78 ± 1.57, 37.93 ± 4.46, and 2.85 ± 1.03 pg/ml for day 0, 6, and 15 
respectively. The average IL-1β concentrations of the synovium tissue homogenate 
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untreated OA controls were 1.78 ± 1.57, 25.41 ± 13.61, and 1.10 ± 0.35 pg/ml 
respectively (Figure 7.7C). Day 6 APS treated synovium homogenate was statistically 
greater than day 0 and day 15 APS treated synovium homogenates (p<0.05). 
 
Figure 7.7: IL-1β concentration represented graphically as average concentrations of IL-1β in single dosed APS 
treated co-cultures compared to OA control co-culture in the following sample mediums: A) cartilage tissue 
homogenates, B) co-culture media, and C) synovium tissue homogenates. # indicates a statistical difference from day 0 
(p<0.05). * indicates a statistical difference between single APS dosed groups (p<0.05). 
The other prominent OA pro-inflammatory cytokine measured was TNF-α. The 
quantitative ELISA analysis completed on the cartilage and synovium tissue 
homogenates resulted in a negligible concentration of TNF-α. Therefore only the co-
culture media (n=4/ time point/ condition) results are presented. The average TNF-α 
concentrations in the APS treated co-culture media were 0.0 ± 0.0, 0.95 ± 0.44, and 1.51 
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± 0.73 pg/ml for day 0, 6, and 15 respectively. The average TNF-α concentrations in the 
co-culture media of the untreated OA control group were 0.0 ± 0.0, 4.75 ± 2.50, and 1.99 
± 1.99 pg/ml respectively (Figure 7.8). In general, IL-1β concentrations were maintained 
within tissue samples for the culture duration and both pro-inflammatory cytokines had 
slight increase throughout the culture duration.  
 
Figure 7.8: TNF-α concentration represented graphically as average concentrations of TNF-α in single dosed APS 
treated co-cultures compared to OA control co-culture in co-culture media samples.  
 The anti-inflammatory cytokines quantitatively measured via ELISAs at day 0, 6, 
and 15 were IL-1ra, sTNF-RI, and sTNF-RII. IL-1ra and sTNF-RII analyses were run on 
cartilage and synovium tissue homogenates (n=4/ time point/ condition/ tissue) and co-
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culture media (n=4/ time point/ condition), however due to sample shortage, only co-
culture media was analyzed for quantitative sTNF-RI concentration.  
The average IL-1ra concentrations for the APS treated cartilage tissue 
homogenates were 10.0 ± 5.67, 86.52 ± 60.11, and 39.66 ± 11.91 pg/ml for day 0, 6, and 
15 respectively. The average IL-1ra concentrations for the OA control groups were 10.0 
± 5.67, 50.61 ± 12.0, and 43.07 ± 23.32 pg/ml respectively (Figure 7.9A). Day 6 APS 
treated cartilage homogenate was statistically greater than the day 0 APS treated cartilage 
homogenate.  
The average IL-1ra concentrations in the APS treated co-culture media samples 
were 0.0 ± 0.0, 1399.21 ± 515.46, and 1675.25 ± 545.39 pg/ml for day 0, 6, and 15 
respectively. The average IL-1ra concentrations for the untreated OA control co-culture 
media were 0.0 ± 0.0, 1995.48 ± 770.69, and 1079.0 ±449.21 pg/ml respectively (Figure 
7.9B). Day 15 APS treated co-culture media was statistically greater than day 0.  
The average IL-1ra concentrations for APS treated synovium tissue homogenates 
were 683.86 ± 439.53, 839.55 ± 19.09, and 991.93 ± 334.66 pg/ml for day 0, 6, and 15 
respectively. The average IL-1ra concentrations for the untreated OA control synovium 
tissue homogenates were 683.86 ± 439.53, 1146.82 ± 273.18, and 1014.54 ± 342.51 
pg/ml respectively (Figure 7.9C).  
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Figure 7.9: IL-1ra concentration represented graphically as average concentrations of IL-1ra in single dosed APS 
treated co-cultures compared to OA control co-culture in the following sample mediums: A) cartilage tissue 
homogenates, B) co-culture media, and C) synovium tissue homogenates. * indicates a statistical difference between 
single APS dosed groups (p<0.05). 
 The average sTNF-RII concentrations in APS treated cartilage tissue 
homogenates were 3.72 ± 1.01, 11.30 ± 1.93, and 3.63 ± 0.68 pg/ml for day 0, 6, and 15 
respectively. The average sTNF-RII concentrations for OA control cartilage tissue 
homogenates were 3.72 ± 1.01, 5.67 ± 0.92, and 2.24 ± 0.71 pg/ml respectively (Figure 
7.10A). Day 6 APS treated cartilage homogenate was statistically greater than its 
respective control (p<0.05). Day 6 APS treated cartilage homogenate was also 
statistically greater than day 0 and day 15 APS treated cartilage homogenate (p<0.05).  
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The average sTNF-RII concentrations of APS treated co-culture media were 0.0 ± 
0.0, 261.51 ± 63.30, and 131.33 ± 44.03 for day 0, 6, and 15 respectively. The average 
sTNF-RII concentrations for untreated OA control co-culture media were 0.0 ± 0.0, 
145.86 ± 24.48, and 75.16 ± 22.51 pg/ml respectively (Figure 7.10B). Day 6 APS treated 
co-culture media was statistically greater than its respective control (p<0.05). Day 6 APS 
treated co-culture media was also statistically greater than day 0 and day 15 APS treated 
co-culture media (p<0.05). As well as day 15 APS treated co-culture media was also 
statistically higher than day 0 media (p<0.05). 
The average sTNF-RII concentrations for APS treated synovium tissue 
homogenates were 61.32 ± 15.26, 35.0 ± 8.73, and 16.74 ± 6.07 pg/ml for day 0, 6, and 
15 respectively. The average sTNF-RII concentrations for OA control synovium tissue 
homogenates were 61.32 ± 15.26, 27.54 ± 4.10, and 11.68 ± 2.23 pg/ml respectively 
(Figure 7.10C). Day 0 APS treated synovium homogenates are statistically greater than 
day 15 Day 0 APS treated synovium homogenates. 
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Figure 7.10: sTNF-RII concentration represented graphically as average concentrations of sTNF-RII in single dosed 
APS treated co-cultures compared to OA control co-culture in the following sample mediums: A) cartilage tissue 
homogenates, B) co-culture media, and C) synovium tissue homogenates. # indicates a statistical difference from day 0 
(p<0.05). * indicates a statistical difference between single APS dosed groups (p<0.05). 
The average sTNF-RI concentrations in APS treated co-culture media were 0.0 ± 
0.0, 247.03 ± 16.47, and 147.33 ± 25.27 for day 0, 6, and 15 respectively. The average 
sTNF-RI concentrations for OA control co-culture media samples were 0.0 ± 0.0, 173.59 
± 13.64, and 135.45 ± 15.24 pg.ml respectively (Figure 7.11). Day 6 APS treated co-
culture media was statistically greater than its respective control (p<0.05). Day 6 APS 
treated co-culture media was also statistically greater than day 0 and day 15 APS treated 
co-culture media (p<0.05). As well as day 15 APS treated co-culture media was also 




Figure 7.11: sTNF-RI concentration represented graphically as average concentrations of sTNF-RI in single dosed 
APS treated co-cultures compared to OA control co-culture in co-culture media samples. # indicates a statistical 
difference from day 0 (p<0.05). * indicates a statistical difference between single APS dosed groups (p<0.05). 
 
DISCUSSION 
 Higher chondrocyte and synovial cell viability was maintained in single dosed 
APS co-cultures compared to untreated OA control co-cultures. APS demonstrates 
possible anti cytotoxic capabilities and shows promising chondroprotective effects. A 
viable synovium is necessary to produce a collection of pro and anti-inflammatory 
mediators, growth factors, and nutrients for the joint including IL-1ra and sTNF-RI& 
RII
34
. APS treated co-cultures also showed potential capabilities in protecting 
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chondrocytes from proliferation, which can also be described as chondrocyte clustering 
and is a hallmark of OA
24
.  
Even though quantitative DNA content analysis presented no statistical difference 
in chondrocyte DNA normalized to tissue weight between APS treated co-culture and 
untreated OA control co-cultures, the ki-67 staining is capable of staining cells in the 
preemptive stages of proliferation such as G1, S, and G2, and DNA content of cells is not 
split and doubled until the M stage (cytokinesis)
79
. Thus, perhaps ki-67 staining is more 
indicative of future proliferation not yet in the appropriate cell cycle stage quantifiable by 
DNA content assays. 
Cartilage fibrillation and relative proteoglycan content was maintained in the APS 
treated cartilage co-culture samples for the culture duration as indicated by OASRI 
assessment. There were no observed histological characteristics of  APS mitigating OA 
progression in the culture duration as APS treated cartilage was not statistically different 
from the OA control co-culture OARSI scores. However, the slight increase in GAG loss 
of the OA control co-culture cartilage compared to the APS treated co-culture cartilage 
could suggest that an enhanced difference in matrix degradation progression could be 
seen at a longer time point than the current culture duration.  
 APS illustrated promising results in not enhancing the inflammatory environment 
by inflicting additional inflammation on the in vitro model. IL-1β and TNF-α 
concentration in the APS treated co-culture media was not statistically different from the 
OA control co-culture concentrations and the pro-inflammatory cytokine concentrations 




well as the IL-1β and TNF-α media concentration was not higher than the low pro-
inflammatory cytokine concentration naturally found in the APS
8
. The IL-1β 
concentration profile in cartilage and synovium tissue homogenates was simply 
maintained and no different from the concentration found in the OA control co-culture 
tissue samples by the end of the culture period. Thus the pro-inflammatory cytokine 
concentration was not aggravated by the addition of APS in co-culture. The spikes in 
media pro-inflammatory cytokine concentration at day 6 could be due to an inflammatory 
response induced by the trauma of the biopsy process as the concentrations seemed to 
acclimate by the end of the culture duration.  
APS demonstrated a potential in mitigating OA progression as all measured anti-
inflammatory cytokine media concentrations of APS treated co-cultures experienced an 
increase in anti-inflammatory cytokine concentration greater than the controls by the end 
of the culture period.  
The peaks in sTNF-RI and RII concentration in the APS dosed co-culture media at 
day 6 are reminiscent of APS leachate sTNF-RI and RII day 3 concentrations (Aim 2) 
and could be a delayed peak correspondence of APS introduction. However, the day 3 
media change has shown to deplete the media of cytokine concentrations. Thus, high 
sTNF-RII concentration in the synovium at day 0 could be a possible hiding place for the 
sTNF-Rs. The cells responsible for producing sTNF-Rs reside in the synovium and could 
have shed their sTNF-Rs throughout the culture duration
58
. The rapidly leached profile of 
sTNF-Rs into the media by day 6 could be from the synovium and the profile was 
enhanced by the sTNF-R leached from the APS dose.  
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In conclusion, a single dose of APS in the in vitro co-culture model showed 
potential in mitigating the progression of OA as it demonstrated possible 
chondroprotective effects against apoptosis and destructive chondrocyte clustering, 
potential reduction in cartilage matrix degradation, and produces a temporary anti-











AIM 4: TO EVALUATE THE EFFICACY OF A DOUBLE DOSE OF APS IN 
MITIGATING OA PROGRESSION IN VITRO AND COMPARE TO THE 




Recent literature has suggested that the limits of the current biological OA 
therapies could be improved if they were developed into a more targeted approach (i.e. in 
alter specific signaling pathways which act to reestablish the homeostasis of joint tissue 
catabolism and anabolism
74,80
).  There has been limited, but encouraging success in using 
targeted anticytokine therapy for OA. The most crucial finding of these studies is the 
need for early delivery of therapies designed to target IL-1β and TNF-α pathways in OA 
pathogenesis
74
. Theoretically, early delivery of cytokine targeted therapy is 
advantageous. As cartilage matrix degradation progresses, the cartilage can degrade until 
no cartilage remains, the particularly long turnaround rate for GAG and collagen II 
synthesis creates an impossible task of late stage regeneration of OA cartilage matrix 
from bone on bone contact
74,81
.  
APS contains a multitude of anti-inflammatory and anabolic growth factors that 
specifically address the prominent IL-1β and TNF-α inflammation pathways found in the 
pathogenesis of OA
8,13
. Therapeutic indications of APS have pointed to its use as an early 
stage OA therapy, but exact dosage has not been investigated. In Aim 2, all cytokine 
concentration profiles of APS seemed to be depleted by day 6 perhaps due to media 
changes. Thus, an additional dose of APS was administered at day 6 (i.e. “double dose”) 
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to determine if this further modified OA progression within the human OA co-culture. In 
order to determine these effects, data obtained from the single dose studies (Aim 3) and 




 Chondrocyte viability was assessed via LIVE/DEAD staining of the OA cartilage 
tissue (n=4/ time point/ condition). The average percentages of chondrocyte viability of 
the double dosed APS cartilage for day 0, 6, and 15 were 97.60 ± 1.28, 89.58 ± 3.90, and 
95.58 ± 1.21% respectively. The average percentages of chondrocyte viability of the 
untreated OA controls were 97.60 ± 1.28, 96.19 ± 1.96, and 96.76 ± 1.31% respectively 
(Figure 8.1A). Replication images were randomly taken throughout the tissue in order to 
accurately represent the cartilage as a whole. There was observed chondrocyte clustering 
(indicative of OA cartilage) throughout the majority of chondrocyte viability images. 
 In general, when comparing single versus double dose groups, there was a trend 
toward an increase of chondrocyte viability in double dosed APS cartilage when 
compared to single dosed APS cartilage. The average percentages of chondrocyte 
viability in single dosed APS cartilage were 96.08 ± 1.55, 80.42 ± 6.37, and 83.19 ± 
6.95% for day 0, 6, and 15, respectively (Figure 8.1B). Overall, chondrocyte viability 





Figure 8.1: Chondrocyte viability represented graphically as a percentage of viable chondrocytes and representative 
images of OA co-culture cartilage tissue where A) compares the effect of double dosed APS chondrocyte viability and 
respective control and B) compares the effect of single and double dosed APS chondrocyte viability with each of their 
respective controls. $ indicates a statistical difference from all other time points and conditions (p<0.05). 
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 Synovial cell viability was also assessed via LIVE/DEAD staining of OA 
synovial tissue (n=4/ time point/ condition). Synovium viability was maintained 
throughout the culture duration in the double dose study. The average percentages of 
synoviocyte viability for the double dosed APS synovium at day 0, 6, and 15 were 66.13 
± 21.61, 76.78 ± 3.56, and 72.17 ± 10.73% respectively. The average percentages of 
synoviocyte viability for the OA control synovium were 66.13 ± 21.61, 84.12 ± 6.48, and 
72.45 ± 6.66% respectively (Figure 8.2A).  
 There was no statistical difference in synoviocyte viability between single and 
double dosed APS synovium as both treated groups seemed to have strikingly similar 
percent viability trends throughout the co-culture time period. The average percentages of 
synoviocyte viability for the single dosed APS synovium at day 0, 6, and 15 were 57.13 ± 
18.30, 73.80 ± 10.92, and 74.05 ± 12.28%, respectively (Figure 8.2B). Overall, 
synovium viability was maintained throughout the culture duration of the single and 




Figure 8.2: Synovial cell viability represented graphically as a percentage of viable synoviocytes and representative 
images of OA co-culture synovium tissue where A) compares the effect of double dosed APS synoviocyte viability and 





 OARSI scoring of the OA co-culture cartilage (n=4/ time point/ condition) 
collected at day 0, 6, and 15 treated with a double dose of APS resulted in an average of 
9.17 ± 1.90, 6.56 ± 2.23, and 4.54 ± 1.53 for day 0, 6, and 15, respectively. The averages 
of the untreated OA controls were 9.17 ± 1.90, 12.28 ± 2.14, and 7.21 ± 1.07 respectively 
(Figure 8.3A). OA control co-culture cartilage was statistically worse than the double 
dosed APS co-culture cartilage at day 6 (p<0.05). There was a general trend of increased 
improvement in OARSI scores of the double dosed APS co-culture cartilage compared to 
the respective OA controls.  
 The average OARSI scores for the single dosed APS cartilage were 6.38 ± 1.77, 
11.22 ± 4.24, and 7.63 ± 2.27 at day 0, 6, and 15, respectively (Figure 8.3B). 
Comparisons of the histological assessments between the effects of a single dose of APS 
and the effects of a double dose of APS concluded that the double dose APS co-culture 
cartilage experienced a statistical improvement in OARSI scores over the single dose 




Figure 8.3: OARSI scores presented graphically with representative images of cartilage samples where A) compares 
the effects of double dosed APS cartilage and respective control and B) compares the effects of single and double 
dosed APS cartilage with each of their respective controls. Red indicates proteoglycan rich ECM, while green indicates 
proteoglycan poor ECM. * indicates statistically difference between APS treatment conditions (p<0.05). 
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IMMUNOHISTOCHEMICAL ANALYSIS  
Semi-quantitative evidence of chondrocyte proliferation via ki-67 staining of 
double dosed APS co-culture cartilage samples (n=4/ time point/ condition) experienced 
statistically increased proliferation from day 0 in day 6 APS treated cartilage and in day 
15 OA control cartilage (p<0.05). The average percentages of positively stained ki-67 
chondrocytes in double dosed APS cartilage were 6.28 ± 1.83, 22.45 ± 5.96, and 16.61 ± 
5.55% for day 0, 6, and 15 respectively. The average percentages of positively stained ki-
67 chondrocytes in untreated OA control cartilage were 6.28 ± 1.83, 8.14 ± 2.13, and 
30.64 ± 10.26% respectively (Figure 8.4A).  
 The average percentages of positively stained ki-67 chondrocytes in the single 
dosed APS cartilage were 19. 05 ± 4.47, 27.12 ± 3.01, and 31.14 ± 9.40% at day 0, 6, and 
15, respectively (Figure 8.4B). There was a general overall increase in chondrocyte 
proliferation in the single and double dosed studies. The single dosed APS co-culture 
cartilage and respective OA control co-culture cartilage experienced a more gradual 
increase in percentage of positively stained ki-67 chondrocytes as the co-culture time 
continued. While the double dosed APS cartilage samples had a more sporadic and less 




Figure 8.4: Chondrocyte proliferation presented graphically as percentages of positively ki-67 stained cells in OA 
cartilage with representative images of cartilage samples where A) compares the effect of double dosed APS 
chondrocyte proliferation and respective control and B) compares the effect of single and double dosed APS 
chondrocyte proliferation with each of their respective controls. Black circles indicate positive brown staining and 





 The quantitative GAG analysis of the double dosed APS co-culture cartilage 
samples (n=4/ time point/ condition) collected at day 0, 6, and 15 resulted in an average 
of 170.70 ± 32.07, 190.86 ± 15.17, and 186.55 ± 15.82 μg GAG /mg dry weight, 
respectively. The average GAG content of the OA control cartilage samples were 170.70 
± 32.07, 188.50 ± 15.49, and 182.15 ± 8.73 μg GAG/ mg dry weight respectively (Figure 
8.5A). There was slight trend in increased GAG maintenance within the double dosed 
APS cartilage compared to the OA control GAG content.  
 GAG contents of the single and double APS treated groups and their respective 
OA controls were maintained throughout the culture duration. The averages of the 
normalized GAG content of the single dosed APS cartilage were 174.34 ± 35.17, 130.75 
± 6.41, and 142.63 ± 23.03 μg GAG/ mg dry weight for day 0, 6, and 15, respectively 




Figure 8.5: GAG content represented graphically as average GAG content normalized to dry weight of A) double 
dosed APS cartilage co-culture samples compared to its respective OA control, B) single dosed APS cartilage co-





The DNA content of OA cartilage samples (n=4/ time point/ condition) was 
quantitatively analyzed and normalized to tissue dry weight at day 0, 6, and 15. The 
average DNA contents normalized to dry weight of the double dosed APS treated 
cartilage were 0.16 ± 0.05, 0.1 ± 0.02, and 0.12 ± 0.01 μg DNA/ mg dry weight for day 
0, 6, and 15 respectively. The average DNA contents normalized to dry weight of the OA 
control co-culture cartilage were 0.16 ± 0.05, 0.18 ± 0.05, and 0.12 ± 0.02 μg DNA/ mg 
dry weight, respectively (Figure 8.6A). In general, DNA content decreased slightly over 
time for the double dosed APS cartilage.  
The average DNA contents normalized to dry weight of the single dose APS 
cartilage were 0.016 ± 0.03, 0.13 ± 0.01, and 0.16 ± 0.03 μg DNA/ mg dry weight for day 
0, 6, and 15 respectively (Figure 8.6B). Overall, the DNA content of the single dose APS 
cartilage co-culture samples was maintained, while the double dose APS cartilage co-




Figure 8.6: DNA content represented graphically as average DNA content normalized to dry weight of A) double 
dosed APS cartilage co-culture samples compared to its respective OA control, B) single dosed APS cartilage co-





The quantitative cytokine analyses were completed on the cartilage and synovium 
tissue homogenates (n=4/ time point/ condition/tissue) as well as the media (n=4/ time 
point/ condition) in order to establish the distribution of the prominent pro and anti-
inflammatory cytokines within the co-culture model. The pro-inflammatory cytokines 
measured were IL-1β and TNF-α. The average IL-1β concentrations of the co-culture 
media of the double dosed APS groups were 0.0 ± 0.0, 15.05 ± 5.67, and 2.31 ± 0.24 
pg/ml for day 0, 6, and 15 respectively. The average concentrations of the untreated OA 
control co-culture media were 0.0 ± 0.0, 3.22 ± 1.25, and 3.43 ± 2.18 pg/ml, respectively 
(Figure 8.7A). Day 6 double dosed APS co-culture media was statistically higher than its 
control, day 0 co-culture media, and day 15 APS treated co-culture media (p<0.05). The 
average IL-1β concentrations of the single dosed APS co-culture media were 0.0 ± 0.0, 
14.82 ± 7.15, and 1.33 ± 0.55 pg/ml for day 0, 6, and 15 respectively (Figure 8.7B).  
 The average IL-1β concentrations of double dosed APS cartilage homogenates 
were 1.27 ± 0.58, 1.19 ± 0.08, and 0.84 ± 0.25 pg/ml for day 0, 6, and 15 respectively. 
The average IL-1β concentrations of the untreated OA control cartilage were 1.27 ± 0.58, 
0.67 ± 0.34, and 0.84 ± 0.25 pg/ml respectively (Figure 8.7C). The average IL-1β 
concentrations of single dosed APS cartilage tissue homogenates were 0.63 ± 0.10, 2.26 
± 1.55, and 0.57 ± 0.19 pg/ml for day 0, 6, and 15 respectively (Figure 8.7D).  
 The average IL-1β concentrations of double dosed APS synovium were 0.77 ± 
0.53, 25.40 ± 18.38, and 12.96 ± 2.90 pg/ml for day 0, 6, and 15 respectively. The 
average IL-1β concentrations of untreated OA control synovium homogenates were 0.77 
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± 0.53, 6.49 ± 0.49, and 8.74 ± 3.62 pg/ml respectively (Figure 8.7E). Day 6 IL-1β 
concentration for double dosed APS synovium tissue homogenates was statistically 
higher than day 0 APS treated synovium tissue homogenates (p<0.05). The average IL-1β 
concentrations of single dosed APS synovium tissue homogenates were 1.78 ± 1.57, 










Figure 8.7:IL-1β concentration represented graphically where A) compares average concentrations between double 
dosed APS co-culture media and their respective untreated OA controls, B) compares average concentrations between 
single and double dosed APS co-culture media and their respective untreated OA controls, C) compares average 
concentrations between double dosed cartilage tissue homogenates and their respective untreated OA controls, D) 
compares average concentrations between single and double dosed APS cartilage tissue homogenate and their 
respective untreated OA controls, E) compares average concentrations between double dosed APS synovium tissue 
homogenates and their respective untreated OA controls, and F) compares average concentrations between single and 
double dosed APS synovium tissue homogenate and their respective untreated OA controls. * indicates a statistical 
difference between APS treated groups (p<0.05). # indicates a statistical difference from a respective OA control 
(p<0.05). 
 117 
Quantitative TNF-α ELISAs were performed on cartilage and synovium tissue 
homogenates as well as co-culture media, however, due to negligible TNF-α 
concentration found in the cartilage and synovium tissue homogenates, only co-culture 
media results were presented. The average TNF-α concentration of the double dosed APS 
treated co-culture media were 0.0 ± 0.0, 7.88 ± 4.55, and 7.69 ± 3.86 pg/ml for day 0, 6, 
and 15 respectively. The average TNF-α concentration of the untreated OA control co-
culture media were 0.0 ± 0.0, 8.0 ± 4.09, and 9.78 ± 6.20 pg/ml respectively (Figure 
8.8A). The average TNF-α concentration of single dosed APS co-culture media were 0.0 








Figure 8.8: TNF-α concentration represented graphically as A) compares average concentrations between double 
dosed APS co-culture media and their respective untreated OA controls and B) compares average concentrations 
between single and double dosed APS co-culture media and their respective untreated OA controls. 
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The anti-inflammatory cytokines quantitatively measured via ELISAs at day 0, 6, 
and 15 were IL-1ra, sTNF-RI, and sTNF-RII. IL-1ra and sTNF-RII analyses were run on 
cartilage and synovium tissue homogenates (n=4/ time point/ condition/ tissue) and co-
culture media (n=4/ time point/ condition), however due to sample shortage, only co-
culture media was analyzed for quantitative sTNF-RI concentration. The average IL-1ra 
concentrations for the double dosed APS co-culture media were 0.0 ± 0.0, 1712.21 ± 
721.62, and 2459.50 ± 997.41 pg/ml for day 0, 6, and 15 respectively. The average IL-1ra 
concentrations for the OA control co-culture media were 0.0 ± 0.0, 1068.66 ± 412.80, and 
2464.50 ± 1276.94 pg/ml respectively (Figure 8.9A). Day 15 APS treated co-culture 
media had a significantly higher IL-1ra concentration than day 0 (p<0.05). The average 
IL-1ra concentrations of single dosed APS co-culture media were 0.0 ± 0.0, 1399.21 ± 
515.46, and 1675.25 ± 545.39 pg/ml for day 0, 6, and 15 respectively (Figure 8.9B).  
 The average IL-1ra concentrations of double dosed APS cartilage tissue 
homogenates were 16.59 ± 8.15, 22.50 ± 6.59, and 54.66 ± 17.28 pg/ml for day 0, 6, and 
15 respectively. The average IL-1ra concentrations of the OA control cartilage 
homogenates were 16.59 ± 8.15, 30.68 ± 15.68, and 106.02 ± 33.54 pg/ml respectively 
(Figure 8.9C). The average IL-1ra concentrations of single dosed APS cartilage tissue 
homogenates were 10.0 ± 5.67, 86.52 ± 60.11, and 39.66 ± 11.91 pg/ml for day 0, 6, and 
15 respectively (Figure 8.9D).  
 The average IL-1ra concentrations of double dosed APS synovium tissue 
homogenates were 325.91 ± 153.79, 592.42 ± 236.34, and 1068.41 ± 275.49 pg/ml for 
day 0, 6, and 15 respectively. The average IL-1ra concentrations for the OA control 
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synovium tissue homogenates were 325.91 ± 153.79, 634.70 ± 208.35, and 1250.80 ± 
351.87 pg/ml respectively (Figure 8.9E). Day 6 IL-1ra concentration of the double dosed 
APS synovium homogenate was significantly higher than day 0 synovium tissue 
homogenate (p<0.05). The average IL-1ra concentrations of the single dosed APS 
synovium tissue homogenates were 683.86 ± 439.53, 839.55 ± 19.09, and 991.93 ± 









Figure 8.9: IL-1ra concentration represented graphically where A) compares average concentrations between double 
dosed APS co-culture media and their respective untreated OA controls, B) compares average concentrations between 
single and double dosed APS co-culture media and their respective untreated OA controls, C) compares average 
concentrations between double dosed cartilage tissue homogenates and their respective untreated OA controls, D) 
compares average concentrations between single and double dosed APS cartilage tissue homogenate and their 
respective untreated OA controls, E) compares average concentrations between double dosed APS synovium tissue 
homogenates and their respective untreated OA controls, and F) compares average concentrations between single and 
double dosed APS synovium tissue homogenate and their respective untreated OA controls. * indicates a statistical 
difference between APS treated groups (p<0.05).  
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The average sTNF-RII concentrations in double dosed APS co-culture media 
were 0.0 ± 0.0, 419.38 ± 64.16, and 293.48 ± 90.87 pg/ml for day 0, 6, and 15 
respectively. The average sTNF-RII concentrations for OA control co-culture media were 
0.0 ± 0.0, 186.10 ± 29.33, and 135.98 ± 39.29 pg/ml respectively (Figure 8.10A). Day 6 
and 15 APS treated co-culture media sTNF-RII concentration was statistically higher 
than day 0 (p<0.05). Day 6 APS treated co-culture media was also significantly higher 
than its respective control (p<0.05). The average sTNF-RII concentrations for single 
dosed APS co-culture media were 0.0 ± 0.0, 261.51 ± 63.30, and 131.33 ± 44.03 for day 
0, 6, and 15 respectively (Figure 8.10B).  
 The average sTNF-RII concentrations of double dosed APS cartilage tissue 
homogenates were 4.02 ± 1.95, 5.17 ± 1.70, and 3.76 ± 1.04 pg/ml for day 0, 6, and 15 
respectively. The average sTNF-RII concentrations for the OA control cartilage 
homogenates were 4.02 1.95, 5.94 ±3.16, and 2.87 ± 0.15 pg/ml respectively (Figure 
8.10C). Day 6 sTNF-RII concentration of the double dosed APS cartilage homogenate 
was statistically higher than day 15 APS treated cartilage homogenate (p<0.05). The 
average sTNF-RII concentrations of single dosed APS cartilage tissue homogenates were 
3.72 ± 1.01, 11.30 ± 1.93, and 3.63 ± 0.68 pg/ml for day 0, 6, and 15 respectively (Figure 
8.10D). Day 6 single dosed APS cartilage tissue homogenate sTNF-RII concentration 
was statistically higher than double dosed APS day 6 cartilage tissue homogenates 
(p<0.05). 
 The average sTNF-RII concentrations of double dosed APS synovium tissue 
homogenates were 45.41 ± 25.09, 40.42 ± 6.61, and 27.09 ±6.18 pg/ml for day 0, 6, and 
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15 respectively. The average sTNF-RII concentration for the OA control synovium tissue 
were 45.41 ±25.09, 35.20 ± 9.90, and 23.86 ± 3.74 pg/ml respectively (Figure 8.10E). 
Day 0 synovium tissue homogenate sTNF-RII concentration was significantly higher than 
day 15 double dosed APS synovium homogenate sTNF-RII concentration (p<0.05). The 
average sTNF-RII concentrations of single dosed APS synovium tissue homogenates 
were 61.32 ± 15.26, 35.0 ± 8.73, and 16.74 ± 6.07 pg/ml for day 0, 6, and 15 respectively 








Figure 8.10: sTNF-RII concentration represented graphically where A) compares average concentrations between 
double dosed APS co-culture media and their respective untreated OA controls, B) compares average concentrations 
between single and double dosed APS co-culture media and their respective untreated OA controls, C) compares 
average concentrations between double dosed cartilage tissue homogenates and their respective untreated OA controls, 
D) compares average concentrations between single and double dosed APS cartilage tissue homogenate and their 
respective untreated OA controls, E) compares average concentrations between double dosed APS synovium tissue 
homogenates and their respective untreated OA controls, and F) compares average concentrations between single and 
double dosed APS synovium tissue homogenate and their respective untreated OA controls. * indicates a statistical 
difference between APS treated groups (p<0.05). # indicates a statistical difference from a respective OA control 
(p<0.05). 
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The average sTNF-RI concentrations of double dosed APS co-culture media were 
0.0 ± 0.0, 459.92 ± 114.54, and 345.34 ± 104.37 pg/ml for day 0, 6, and 15 respectively. 
The average sTNF-RI concentrations for their untreated OA controls were 0.0 ± 0.0, 
291.75 ± 66.38, and 206.54 ± 31.76 pg/ml respectively (Figure 8.11A). Day 6 and 15 
APS treated sTNF-RI concentrations were both statistically higher than day 0 co-culture 
media sTNF-RI concentrations (p<0.05). The average sTNF-RI concentrations of single 
dosed APS co-culture media were 0.0 ± 0.0, 247.03 ± 16.47, and 147.33 ± 25.27 for day 
0, 6, and 15 respectively (Figure 8.11B). Day 6 double dosed APS co-culture media 
experienced significantly higher sTNF-RI concentrations than day 6 single dosed APS 







Figure 8.11: sTNF-RI concentration represented graphically where A) compares average concentrations between 
double dosed APS co-culture media and their respective untreated OA controls and B) compares average 
concentrations between single and double dosed APS co-culture media and their respective untreated OA controls. * 
indicates a statistical difference between APS treated groups (p<0.05). # indicates a statistical difference from a 




 Chondrocyte viability was maintained in the double dose APS cartilage samples 
throughout the culture duration and the additional dose of APS seemed to have offer 
greater chondroprotective effects than a single dose of APS. However, it is important to 
note that the single dose and double dose studies were performed on separate donor 
populations and as discussed in previous chapters, the interpatient variability of human 
subjects can be high  
Synovium viability was also maintained throughout the culture duration. The 
viable cartilage and synovium supports the cells necessary to continue either pathological 
OA progression, or theoretically, mitigation of OA. The additional APS dose seemed to 
offer some protection against chondrocyte cloning as the double dose APS cartilage 
experienced an advantageous decrease in chondrocyte proliferation compared to its 
respective OA control cartilage than the single dose APS cartilage experienced. This 
decrease in chondrocyte proliferation is corroborated with the quantitative DNA content 
analysis.  
 Double dose APS cartilage experienced a statistical improvement in surface 
fibrillation and relative retained proteoglycan content compared to single dose APS 
cartilage (p<0.05). This could be due to a theoretically prolonged anti-inflammatory 
milieu that an additional dose of APS could present in in vitro conditions. The double 
dose APS cartilage demonstrated a greater ability to maintain GAG content throughout 
the culture duration; however the OA control cartilage did not exhibit the characteristic 




. A longer culture time could enhance the differences in GAG reduction 
between the treatment group and the OA control group or increasing the statistical power 
of an experiment by increasing the sample size could present a greater variability 
between the treatment group and the OA control group.  
 Both dosing regimens experienced peaks in IL-1β concentration in the cartilage, 
synovium, and co-culture media mid culture, but the concentrations drop to physiologic 
values by the end of the culture duration. The temporary mid culture spike of pro-
inflammatory cytokine concentration could be a delayed effect of APS introduction, but 
the double dose study concentrations are lower than the single dose. The pro-
inflammatory concentration spikes superseded the levels typically found in APS
8
; this 
could suggest that APS produces a temporary inflammatory reaction in vitro. The delayed 
response poses an interesting theory where cytokines infiltrate a tissue with greater 
porosity (synovium) to later gradually leach into the co-culture and attempt to infiltrate 
and promote OA pathways in denser tissue (cartilage) at a delayed time. However, the 
additional dose of APS did not cause any additional inflammation to the in vitro 




 IL-1ra concentration within OA cartilage, synovium, and co-culture media tended 
to increase more gradually in the double dose study then the concentration of the single 
dose study, but by the end of the culture duration an increase in IL-1ra of the OA control 
sample mediums compared to the APS treated sample mediums. This increase in IL-1ra 
concentration could be present in order to combat the severe OA progression experienced 
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in those particular double dose OA control samples as indicating with increased cartilage 
degradation and chondrocyte cloning. sTNF-R trends in the double dose study mirror 
those of the single dose study where all co-culture sample mediums exhibited increased 
anti-inflammatory concentration in the APS treated groups compared to OA controls by 
the end of culture duration. 
The additional APS dose exhibited a greater potential of improving OA mitigation 
in vitro than a singular APS dose by providing increased chondroprotective effects, 
decreased potential of chondrocyte cloning, improved matrix degradation, and an anti-
inflammatory milieu.  





OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
CONCLUSIONS 
OA is a debilitating disease whose inflammatory environment leads to the 
destruction of all tissues in the joint space, especially the degradation of cartilage. APS 
poses as a potential OA mitigation therapy due to its extensively characterized for pro 
and anti-inflammatory and anabolic mediators that could modify disease progression. 
Another promising aspect of APS is its classification as a medical device and therefore it 
has a less extensive pathway to market and can be accessed quicker than other 
therapeutics following traditional biologic regulatory pathways.  
The objectives of this research were to establish an in vitro OA model in order to 
evaluate the potential OA mitigation of APS in a long term culture. The effects of a 
single and double dose of APS were assessed in an in vitro OA model to evaluate the 
characteristic hallmarks of OA and determine the capability of APS to modify disease 
progression. 
o A human in vitro OA model was established by simultaneously co-culturing OA 
cartilage and OA synovium. 
o The co-culture model successfully demonstrated its ability to mimic OA 
pathogenesis with: cartilage degradation in response to an inflammatory 
milieu, gradual tissue destruction progression over time, and 
representative feed-forward progression where each tissue contributes to 
the other’s demise. 
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o  APS placed in co-culture demonstrated a considerable depletion pro and anti-
inflammatory mediator profile by mid-culture. 
o A single dose of APS showed encouraging results in mitigating OA as APS 
treated co-culture cartilage experienced less chondrocyte cloning and a general 
increase of anti-inflammatory mediators within the OA environment.  
o Comparing a single and double dose of APS revealed more promising results for 
the potential of APS to mitigate OA as a second dose of APS decreased 
chondrocyte cloning and significantly improved cartilage degradation over a 
single dose of APS.  
o Double dose study also mirrored the general increase of anti-inflammatory 
mediators within the OA environment found in the single dose study. 
FUTURE DIRECTIONS  
Even though this project was a comprehensive analysis on the effect of APS on a 
human explant co-culture model, there was a remaining unstudied component of APSs 
possible mechanism of action. Only lysed APS was able to be used in this model as the 
surgeon required two weeks of time to replenish blood in between the blood draw and the 
cartilage and synovium collection the day of their TKA surgery. Thus, an interesting 
future direction would be to use live APS in order to assess the cytokine profiles from 
leaching from pure APS and cytokine production stimulated by APS on the co-culture 
model. A greater insight into the mechanism of action of APS could be ascertained from 
such a study. However, a greater level of communication between the surgeon and 
stricter donor inclusion criteria would need to be generated in order to sort out a younger 
 132 
population of donors that could handle a peripheral blood draw the day of the surgery. 
A caveat throughout the project has been small sample sizes of human tissue. Due 
to high interpatient variability typically found in human studies, a larger sample size for 
future human co-culture model studies should be used in order to obtain statistical power. 
Past studies of colleagues have found that a donor size of at least 10 donors is necessary 
when using this particular OA human explant co-culture model.  
It would also be interesting to evaluate the mitigation effects of APS in a co-
culture model for a longer time period. As OA is a progressive disease that can take years 
to progress fully to severe stages, it would be worthwhile to not only assess a month long 
co-culture period, but also to create a dynamic model where physiologic movement of the 
knee was incorporated into a co-culture model. An additional outcome parameter of this 
study would be a gene expression analysis of the cartilage to assess delayed responses 
within the tissue. 
 The interpatient variability of this study could’ve been improved by using the 
same donor population for the single and the double dose studies. Variability could also 
be decreased by splitting the tissue biopsies in half in order to use one portion as the 





APPENDIX A: RECOMBINANT PRO-INFLAMMATORY CYTOKINE MEDIA 
DOPING OF IN VITRO HUMAN EXPLANT CARTILAGE CULTURE MODEL 
 
INTRODUCTION 
**Note: Studies herein contain abnormalities 
 APS has proven an effective potential OA therapy in the use of in vitro OA 
animal models where recombinant cytokines create an accelerated OA pathological 
progression on healthy cartilage explants. The previous aims described in this thesis all 
used a human explant co-culture model derived from late stage OA cartilage and 
synovium and rely on the natural excretion of inflammatory and matrix degrading 
mediators to further OA progression; however, that natural human progression model is 
only effective in detecting statistical differences with large sample sizes. Thus a model 
was created using experimental components from both recombinant cytokine doping 
animal model and natural human co-culture model in order to detect statistical differences 
with smaller sample sizes and to compare our human model to other pro-inflammatory 
cytokine doping models.  
 The new model consisted of a human explant cartilage only culture model, but 
with the addition of recombinant human IL-1β and TNF-α to synergistically and rapidly 
progress OA in vitro as oppose to using the natural feed-forward progression from a 
human OA cartilage and synovium co-culture. The more accelerated human model would 
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potentially be able to detect more subtle differences in culture of the measured outcomes 
in order to hopefully determine more statistical power of in vitro APS treatment.  
 
METHODS AND MATERIALS 
CARTILAGE COLLECTION AND CULTURING CONDITIONS 
 Only human OA cartilage were collected with informed consent under the same 
IRB (Greenville Health System) approved protocol (Pro00039016) as chapter four. The 
collection and biopsy methods were slightly modified from those previously outlined in 
chapter 4 and all materials and methods not specified in the appendix should be assumed 
consistent with those in chapter 4. Five 6 mm cartilage biopsies were obtained from each 
of the 3 human donors from the portions of the femoral condyle that were furthest from 
the observed primary defect in hopes to obtain minimally fibrillated samples for proper 
accelerated OA pathogenesis progression. Each 6 mm biopsy was cut in half and placed 
in culturing conditions seen in Figure A-1.  
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Figure A-1: Plate layout of the recombinant pro-inflammatory cytokine doped media and OA control cartilage biopsy 
trans-well plate. 
The half portions of the 6 mm cartilage biopsies were cultured in “APS”, “no 
APS”, or “OA control” groups where APS and no APS groups received doping media 
and the OA control group received the culturing media described in chapter 4. The 
doping media consisted of the culturing media from chapter 4 with the addition of 10 
ng/ml of each human recombinant IL-1β (PeproTech, 200-01B-2UG) and TNF-α 
(PeproTech, 300-01A-10UG). All half portions of the 6 mm biopsies were placed in a 12 
well trans-well plate according to Figure A-1 with 1.5 mLs of culturing media and only 
the APS group was preincubated for 1 hour with 250 μLs of APS and 250 μLs of 
culturing media in the insert. After the preincubation hour, the APS group’s and the no 
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APS group’s culturing media was replaced with 1.5 mLs of doping media in the bottom 
of the wells. The APS group had 250 μLs of doping media placed in their inserts and the 
no APS group had 500 μLs of doping media placed in their inserts. The OA control group 
had 500 μLs of culturing media placed in their respective inserts at that time. The trans-
well plate was placed in a humidified incubator at 37°C and 5% carbon dioxide and 
respective doping and culturing media was replaced every third day for a 15 day duration.  
 
SAMPLE PREPARATION FOR ANALYSIS 
Tissue and media samples were collected at day 6, 12, and 15. Media samples 
were collected in 2 ml aliquot tubes and immediately frozen at -80°C for future analyses 
not included in this work. Cartilage tissue samples were cut into two pieces where one 
portion was used for chondrocyte viability analysis via LIVE/DEAD assay and prepared 
for histological analyses described in chapter 4. The other portion was used to determine 
GAG content via DMMB assay also described in further detail in chapter 4. The 
flowchart outlined in Figure A-2 shows the order of processes involved in the pro-
inflammatory media doping study.  
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Figure A-2: Doping model analyses flowchart of the analyses competed for the pro-inflammatory media doping of in 




 The chondrocyte viability was measured via a LIVE/DEAD assay at day 0, 6, 12, 
and 15. The average percent viability of the APS treated pro-inflammatory cytokine 
doped cartilage explants were 92.20 ± 1.74, 32.05 ± 32.05, 12.35 ± 10.55, and 0.0 ± 0.0 
% viability for day 0, 6, 12 and 15 respectively. The average percent viability of the non 
APS treated pro-inflammatory cytokine doped cartilage explants were 92.20 ± 1.74, 
49.48 ± 25.46, 51.86 ± 28.93, and 17.18 ± 17.18 % viability respectively. The average 
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chondrocyte viabilities for the OA control cartilage explants were 92.20 ± 1.74, 59.12 ± 
15.88, 40.60 ± 16.44, and 44.44 ± 29.40 % viability respectively (Figure A-3). The APS 
treated cartilage explants at day 12 and 15 had statistically decreased chondrocyte 
viability as did the non APS treated cartilage explant at day 15. In general chondrocyte 
viability decreased in all treatment and control groups throughout the culture time period.  
 
Figure A-3: Chondrocyte viability of the OA cartilage explants in pro-inflammatory doped media and treated with 
either APS or no APS and compared to the viability of a natural OA control cartilage explant. # indicates statistical 







The GAG content of the cartilage explants was analyzed via DMMB assay at the 
tissue collection time points. The average GAG contents of the APS treated pro-
inflammatory cytokine doped media cartilage explants were 159.66 ±20.05, 85.49 ± 
35.03, 43.0 ± 10.18, and 36.31 ± 10.36 μg GAG / mg dry weight for day 0, 6, 12, and 15 
respectively. The average GAG contents of the non APS treated pro-inflammatory 
cytokine doped media cartilage explants were 159.66 ± 20.05, 48.47 ±11.40, 120.01 
±115.88, and 44.89 ± 8.55 μg GAG/ mg dry weight respectively. The average GAG 
content of the OA control cartilage explants were 159.66 ± 20.05, 41.64 ±3.59, 40.82 ± 
11.94, and 35.82 ± 9.07 μg GAG/ mg dry weight respectively(Figure A-4). All values for 
all treatment groups were statistically different from day 0. Also, day 6 APS treated GAG 
content was significantly decreased by the day 15 APS treated cartilage explant. Overall, 
GAG content significantly dropped from day 0 and the observed evidence of the 
histological analyses provided befitting visualization of these results.  
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Figure A-4: GAG content of the OA cartilage explants in pro-inflammatory doped media and treated with either APS 
or no APS and compared to the GAG content of a natural OA control cartilage explant. * indicates statistically different 




 The cartilage explants were assessed for broad proteoglycan content and general 
ECM devoid of proteoglycan content via Safranin-O/ Fast-green staining respectively in 
order to be analyzed by OARSI scoring. The average OARSI scores of the APS treated 
pro-inflammatory cytokine doped media cartilage explants were 6.67 ± 2.89, 14.0 ± 0.0, 
12.89 ± 0.59, and 12.89 ± 0.59 for day 0, 6, 12, and 15 respectively. The average OARSI 
 141 
scores of the non APS treated pro-inflammatory cytokine doped media cartilage explants 
were 6.67 ± 2.89, 12.89 ± 0.59, 13.11 ± 0.59, and 14.22 ± 0.99 respectively. The average 
OARSI scores for the OA control cartilage explants were 6.67 ± 2.89, 11.44 ± 1.28, 12.67 
± 0.38, and 14.0 ± 1.63 respectively (Figure A-5). According to OARSI scoring, all 
cartilage explants samples, regardless of treatment, experienced significantly worse 
cartilage fibrillation and proteoglycan content depletion by day 6 and was maintained 
throughout the remainder of the culture time period.  
 
Figure A-5: OARSI scores of the OA cartilage explants in pro-inflammatory doped media and treated with either APS 
or no APS and compared to the OARSI scores of a natural OA control cartilage explant. The representative images 
illustrate the severity of proteoglycan depletion the cartilage explants underwent starting from early in the culture time 




ALCIAN BLUE STAINING FOR RELATIVE GAG CONTENT  
The Alcian Blue/ Nuclear Fast Red staining was also performed to further 
illustrate specific GAG content and general chondrocyte populations respectively within 
the cartilage explants. The ImageJ analysis of the percent of area stained positively for 
GAG content resulted in an average of 85.27 ± 9.72, 31.31 ± 19.88, 44.33 ± 4.20, and 
38.62 ± 15.48 % for day 0, 6, 12, and 15 respectively of the APS treated media doped 
cartilage. The media doped cartilage that was not treated with APS had an average 
percent area stained positively for GAGs of 85.27 ± 9.72, 40.63 ± 12.20, 44.23 ± 14.38, 
and 29.72 ± 9.32 % respectively. The averages of the percent area stained positively for 
GAGs of the OA control cartilage were 85.27 ± 9.72, 53.29 ± 6.86, 49.50 ± 19.47, and 
39.12 ± 14.0 % respectively (Figure A-6). All day 15 groups were statistically lower than 
the OA control percent area stained positively for GAG at day 0. There was a large drop 
in percent area stained for GAG by day 6 for all treatment groups and control that 
continues for the remainder of the study. This similar decrease of in the percent area 
stained for GAGs across all groups suggests that the OA control was GAG depleted at a 
similar rate to the pro-inflammatory cytokine doped media cartilage samples.  
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Figure A-6: Percent area of Alcian blue stained cartilage depicted graphically as the percent area stained positively 
for GAG content with representative images of the Alcian Blue/ Nuclear Fast Red stained cartilage samples. Blue 
indicates GAG in ECM and pink indicates a nuclei. # indicates statistically different from day 0 (p<0.05). 
 
DISCUSSION 
 The chondrocyte viability of the cartilage explants, regardless of treatment group, 
were severely decreased throughout the culture time period to the point where the APS 
treated group at day 15 had 0.0 % chondrocyte viability. A possible reason for this 
intense viability reduction was a malfunction of the incubator during the culture time 
period of all three donor trans-well plates. The malfunction caused a possible 
contamination in the trans-well plates that was visible by day 15 (not pictured). 
 144 
Unfortunately, due to this contamination the validity of the results of the pro-
inflammatory cytokine doped media study were compromised.  
 The pro-inflammatory cytokine doped media was intended to accelerate OA 
progression of the cartilage explants without the aid of the pathological feed-forward 
progression usually given by the synovium in vivo
6
. However, the concentration of the 
synergistic pro-inflammatory cytokines in the media seemed to have almost entirely 
depleted the GAG content before the halfway point in the culture time period as 
confirmed in the DMMB assay results, OARSI scoring, and Alcian Blue/ Nuclear Fast 
Red stained images. Pro-inflammatory cytokine doping models that use animal tissue use 
much higher concentrations (up to 1000 fold) of both recombinant pro-inflammatory 
cytokines and have not experienced severe matrix destruction throughout the entire 
culture duration
76,82
. Such early GAG depletion of the cartilage explants was an over 
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